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Peroxidasin is a rising star in the field of redox biology. It is a peculiar heme 
peroxidase that uniquely contains non-catalytic domains in addition to the 
peroxidase domain. Peroxidasin catalyses the formation of an unusual sulfilimine 
bond between methionine and hydroxylysine in the non-collagenous domain of 
collagen IV in the extracellular matrix (ECM). The mechanism is proposed to involve 
the generation of hypobromous acid (HOBr) in a rare example of an anabolic 
function of this powerful oxidant and destructive bactericide. Peroxidasin is 
implicated in many pathologies, including cardiovascular diseases, fibrosis and 
cancer. A lot is unknown about the exact mechanism of collagen IV cross-linking, 
the substrate specificity and selectivity of peroxidasin, and regulation of its activity. 
One of the main questions that surrounded peroxidasin since its discovery is 
whether it causes collateral oxidative modifications of biomolecules. 
In this thesis, I investigated the selectivity and modulation of the activity of 
peroxidasin in the ECM. I optimised an in situ model system and confirmed the 
activity of peroxidasin embedded in the ECM. The results demonstrate that 
peroxidasin is highly efficient in cross-linking collagen IV using low concentrations 
of bromide and hydrogen peroxide. Peroxidasin catalyses the oxidation of 
exogenous NADH to bromohydrin, providing direct evidence that it generates free 
HOBr in the decellularised ECM. I investigated the modulation of collagen IV cross-
linking by peroxidase substrates and scavengers of HOBr. Physiological levels of 
thiocyanate and urate modulate collagen IV cross-linking. Overall, peroxidasin 
shows preference for bromide over other physiological substrates, although the 
basis of this specificity is not yet known. Scavengers of HOBr, like methionine and 
glutathione are inefficient in inhibiting the sulfilimine bond in collagen IV. These 
observations demonstrate selectivity of the reactions of HOBr produced by 
peroxidasin for collagen IV cross-linking.  
I investigated whether HOBr produced by peroxidasin in the ECM undergoes 
reactions beyond cross-linking collagen IV. I developed mass spectrometry 
iv 
 
methods to measure markers of oxidative modifications of proteins. The results 
show that peroxidasin indeed catalyses the formation of 3-bromotyrosine, a specific 
marker of the reaction of HOBr with tyrosine. The levels of 3-bromotyrosine on 
proteins are significantly lower when peroxidasin is inhibited or knocked out. 
Formation of 3-bromotyrosine is more susceptible to inhibition by thiocyanate, 
urate and nitrite than the cross-linking of collagen IV. These results suggest 
selectivity of HOBr reactions towards the deliberate sulfilimine bond formation 
over the presumably collateral reactions with other amino acid residues on 
proteins. 
Taken together, the evidence I present here demonstrates that the reactions of 
peroxidasin in the ECM are highly specific for, but not limited to, the cross-linking 
of collagen IV. It strengthens the hypothesis that HOBr generated by peroxidasin is 
targeted towards collagen IV, though likely to diffuse a short distance in the ECM. 
The novel finding that peroxidasin contributes to the formation of 3-bromoytrosine 
on proteins brings it to the fore as an enzymatic source of oxidative modifications 
of proteins. It also raises more questions about the extent and effect of peroxidasin-
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 Chapter 1 Introduction 
 
Peroxidasin rose to fame as the enzyme that catalyses an unusual sulfur-nitrogen 
cross link in collagen IV. It attracted attention as a peculiar new member of the 
exclusive mammalian heme peroxidases. In addition to the catalytic domain, which 
displays high sequence homology in all peroxidases, peroxidasin uniquely contains 
additional domains that facilitate its interaction with other proteins. The main 
known physiological function of peroxidasin is to catalyse the formation of an 
essential sulfilimine bond in collagen IV. This intermolecular bond is crucial for the 
functionality and integrity of the basement membrane, a specialised form of the 
extracellular matrix (ECM). Though it has not been directly demonstrated, the 
mechanism is thought to involve the oxidation of bromide to hypobromous acid, 
which then promotes the cross link between methionine and hydroxylysine 
residues joining two protomers of collagen IV. Recently, peroxidasin has been 
shown to be involved in various pathological processes, including kidney fibrosis, 
developmental glaucoma and many types of cancer. 
There are many questions surrounding the mechanism of sulfilimine cross link 
formation and the enzymology of peroxidasin. Does peroxidasin undergo a 
concerted reaction with collagen IV or release HOBr into its surroundings? Does 
HOBr react with other components of the ECM? What are the effects of other 
physiological peroxidase substrates on the activity of peroxidasin? This research 
project addresses some of the questions regarding the enzymology of peroxidasin 
and the specificity of the oxidation reactions. 
In this chapter, I review the literature on mammalian heme peroxidases, focusing 
on the current knowledge on peroxidasin structure, function, reaction mechanism 
and role in diseases. I summarise the relevant literature on the production of 




oxidants and oxidative modifications of biomolecules. I also review what is known 
about the physiology and pathology of the ECM and collagen IV.  
1.1. Mammalian heme peroxidases 
The mammalian heme peroxidases are a group of enzymes that contain a conserved 
catalytic peroxidase domain. They activate hydrogen peroxide to oxidise organic 
substrates and halides (1). It is a distinct group from other peroxidases (plant, 
fungal, bacterial) and they have evolved convergently (2-4). Peroxidases contain a 
heme group with Fe(III) bound to the four pyrrole nitrogens (Figure 1). The fifth 
coordination position (proximal) is bound to the imidazole nitrogen on a histidine 
residue, while the sixth coordination position (distal) remains vacant in the native 
enzyme and forms a Fe(IV)=O linkage when oxidised by hydrogen peroxide (1).  
The mammalian heme peroxidases include myeloperoxidase (MPO), 
lactoperoxidase (LPO), eosinophil peroxidase (EPO), thyroid peroxidase (TPO), and 
peroxidasin (PXDN). Sequence alignment of the five human heme peroxidases 
reveals that the key catalytic residues (Gln, His, Arg, Asn) as well as the residues 
involved in the two covalent links with the prosthetic group (Asp and Glu) are all 
conserved. The calcium binding sequence (LTS-XX-DAS) is also conserved (2). 
 
Figure 1. The heme structure of the active site of peroxidases. The reaction of the 
Fe(III) with hydrogen peroxide lead to the formation of Fe(IV)=O in compound I. 
  




The catalytic function of mammalian heme peroxidases involves the oxidation of a 
substrate using hydrogen peroxide (H2O2) as a co-substrate. Peroxidases can 
catalyse two types of reactions: peroxidation and halogenation (Figure 2). The 
catalytic cycle starts when H2O2 reacts with the native enzyme (ferric), to generate 
compound I (oxy-ferryl). Compound I can then enter the halogenase cycle in which 
it catalyses two-electron oxidation of halides (chloride, bromide and iodide), and 
the pseudohalide thiocyanate, which regenerates the native enzyme. Compound I 
can also enter the peroxidase cycle in which it catalyses two sequential one-electron 
oxidation steps of organic substrates producing radicals (2, 5, 6).    
Mammalian heme peroxidases oxidise a variety of physiological substrates for 
diverse biological functions. MPO mainly oxidises chloride producing the 
bactericidal hypochlorous acid inside the phagosomes of stimulated neutrophils 
(7). LPO oxidises thiocyanate to produce hypothiocyanous acids in saliva (8, 9). EPO 
produces hypobromous acid when eosinophil granulocytes are stimulated (10). 
TPO produces hypoiodous acid for the biosynthesis of thyroid hormones (11). 
Plasma concentrations of some physiological substrates and the rate constants for 
their reactions with peroxidases are summarised in Table 1. In addition to their 
beneficial physiological roles, peroxidases can also cause harm. The highly reactive 
hypohalous acids produced by peroxidases react with many biomolecules and can 
damage the invading pathogens as well as the host tissues, especially during 
inflammation (5, 12). 
 





Figure 2. The catalytic cycles of animal heme peroxidases. The native enzyme is 
oxidised by hydrogen peroxide to Compound I, which can then undergo two-electron 
reduction (halogenase cycle), or two consecutive one-electron reduction (peroxidase 
cycle), and return back to the native enzyme. RH*= organic substrate, R= organic radical, 
X⁻= halide, HOX= hypohalous acids. 
 
Table 1. Peroxidases and their substrates. Plasma concentrations of some of the 
physiological peroxidase substrates and the rate constants for their reactions with 
peroxidases (13, 14).  
 Plasma 
concentrations 
hsPxd01-con4* MPO EPO LPO 
Chloride 140 mM 0 2.5 ⨯ 104 0.31 ⨯ 104 0 
Bromide 20-100 µM 5.6 ⨯ 106 1.1 ⨯ 106 1.9 ⨯ 107 4.1 ⨯ 104 
Iodide 100-500 nM 1.68 ⨯107 7.2 ⨯ 106 9.3 ⨯ 107 1.2 ⨯ 108 
Thiocyanate 20-120 µM 1.83 ⨯ 107 9.6 ⨯ 106 10 ⨯ 107 2 ⨯ 108 
* hsPxd01-con4 = a truncated recombinant human peroxidasin that contains peroxidase 
and Ig domains.  
  





1.2.1 History  
Peroxidasin was first discovered in 1994, when Nelson et al. isolated and 
characterised the protein from Drosophila cells in culture (15). Peroxidasin was 
found in the hemocytes; migratory cells in the hemolymph which are involved in 
ECM deposition and destruction of apoptotic cells. Based on analysis of its structure 
and spatio-temporal expression, peroxidasin was hypothesised to be involved in the 
consolidation of the ECM, pathogenic defense and phagocytosis (15). Five years 
later, a homolog of Drosophila peroxidasin gene was found to be upregulated in p53-
dependent apoptotic cells in a human colorectal cancer cell line (16). This gene, 
named p53-responsive gene 2 (PRG2), was not well characterised but hypothesised 
to have a role in apoptosis induced by reactive oxygen species. The PRG2 mRNA is 
expressed in most normal human tissues, with the highest expression in the heart, 
placenta, spleen, ovary and intestines (16). Shortly after, the melanoma gene 
(MG50) was reported in a human squamous lung carcinoma cell line (17). The 
sequence of the MG50 product has 75% homology to the Drosophila peroxidasin. 
Based on homology with other genes, MG50 was hypothesised to code for the IL-1 
receptor antagonist protein, a pro-inflammatory cytokine (17). Eight years later, 
two other homologs of Drosophila peroxidasin were found in humans by a sequence 
homology search (18). These two proteins were termed vascular peroxidases 
(VPO1 and VPO2) because they were thought to be mostly expressed in the vascular 
system. The peroxidase domain of human and mouse VPO1 is highly homologous to 
that in other heme peroxidases (MPO, EPO, LPO and TPO). RT-PCR showed that 
VPO1 mRNA is expressed in many embryonic and adult tissues. However, the 
protein was only found in the heart tissues and vascular wall as measured by 
western blotting (18). In this study, Cheng et al. also reported detection of high 
levels of VPO1 (~1 µM) circulating in normal human plasma. A later study reported 
that plasma VPO1 is enzymatically active (19). VPO2, alternatively named 
peroxidasin 2, or peroxidasin-like protein (PXDNL) is catalytically inactive. It is only 
expressed in the human heart and elevated in the failing heart (20). A third human 




peroxidasin, which is nearly identical to peroxidasin 2 is thought to be a splicing 
variant (21). 
It is worth noting that the naming of VPO1 is controversial and seems redundant. 
The protein itself is not different from the one discovered by Nelson et al in 1994 
(15), which most of the published literature refers to as peroxidasin. In this thesis, 
I use peroxidasin (PXDN) to refer to peroxidasin 1, the catalytically active enzyme. 
Peroxidasin was confirmed to be produced by human primary cells, such as 
fibroblasts (22). Immunofluorescence labelling revealed that peroxidasin co-
localises intracellularly with the endoplasmic reticulum, as well as extracellularly 
in fibril-like structures. A homolog of Drosophila peroxidasin was reported in 
Xenopus tropicalis, with high expression in the neural tube and pronephros during 
development, and later in adult kidney (23). These reports in invertebrates and 
vertebrates all pointed to a novel evolutionarily conserved heme peroxidase. The 
following sections outline the current knowledge on the structure, function and 
reaction mechanism of peroxidasin, as well as its role in disease. 
1.2.2 Structure  
Peroxidasin is a large protein with several domains and linking regions (15). 
Arrangement and model structures of peroxidasin domains are shown in Figure 3 
and Figure 4. The hydrophobic signal peptide at the N-terminal is for secretion of 
the protein to the extracellular space (15, 21, 24). The next domain contains five 
leucine-rich repeats (LRRs), which is a common feature in proteins that function in 
protein-protein interactions, cell adhesion and signalling (15, 21). A flanking region 
connects the LRRs to four immunoglobulin-loop (Ig) motifs, which are ubiquitous 
and play a variety of roles, mainly in cell adhesion. The enzymatically active 
peroxidase domain is highly homologous to the catalytic domains of other 
mammalian heme peroxidases (~40 % identical and >20 % similar amino acid 
sequence to other mammalian peroxidases), with the highest similarity to 
lactoperoxidase (15). The peroxidase domain forms α-helical structures, with a 
heme group in the centre. The sequence contains ten conserved cysteine residues 




involved in disulfide bridges (21, 25). A multiple sequence alignment shows that the 
key catalytic and metal binding residues are conserved, including the distal His, Gln, 
and Arg and the proximal His and Asn (Figure 5). Flanking the peroxidase domain 
on the C-terminus is the von Willebrand factor type C domain (VWC), which features 
in a large number of ECM proteins. This domain was thought to be involved in the 
trimerisation of peroxidasin. However, a recent study showed the alpha-helical 
linker region located between the peroxidase and the VWC domains is actually the 
crucial sequence for trimerisation (26). 
The peroxidasin monomer has a molecular weight of ~ 165 kDa. Three monomers 
are linked by disulfide bonds to form a homotrimer that has a size of ~500 kDa 
(Figure 6) (15, 24). Oligomerisation of peroxidasin into a trimer occurs 
intracellularly (26). Trimerisation is not necessary for catalytic activity, as 
monomeric peroxidasin is equally active. However trimerisation is essential for the 
incorporation in the ECM and optimal cross-linking of collagen IV (24). The native 
trimeric peroxidasin was found in the endoplasmic reticulum and on the cell 
surface. When a cysteine residue was mutated to stop it from trimerising, the 
monomeric construct was not detected on the cell surface, indicating that 
oligomerisation is necessary for the attachment of secreted peroxidasin to the cell 
surface. 
Peroxidasin is post-translationally modified by N-glycosylation at eleven sites (25) 
and cleavage by proprotein convertases close to its C-terminus. Truncation of the 
VWC domain enhances its enzymatic activity and provides a regulatory mechanism 
for its function (27). The multiple domains and overall structure of peroxidasin 
make it the most structurally complex mammalian heme peroxidase. Interestingly, 
peroxidasin is proposed to be the ancestral enzyme of the animal heme peroxidase 
family, with the loss of the non-catalytic domains giving rise to TPO, LPO, EPO, and 
MPO (Figure 7) (28). 
  





Figure 3. Domain arrangement of peroxidasin. Schematic presentation of the linear 
arrangement of peroxidasin domains, including the secretory signal (S), leucine rich 
repeats (LRR), immunoglobulin domains (Ig), peroxidase domain and von Willebrand 




Figure 4. Model structures of peroxidasin domains.  Models for (a) LRR domain, (b) four 
Ig domains, (c) VWC domain and (d) peroxidase domain. Inset shows the active site of 
peroxidasin with the heme- and calcium-binding amino acid residues. The peroxidase 
model is constructed using homologous goat LPO as a template. The crystal structure of 
peroxidasin has not been solved yet. Adapted from (25, 29). 
  





Figure 5. Amino acid sequence of the peroxidase domain of peroxidasin. Residues 
conserved across human PXDN, MPO, LPO, TPO and EPO are enclosed in an open box. 
Catalytic residues are highlighted in red. Residues that bind prosthetic group are 
highlighted in grey. Residues that bind to calcium are highlighted in yellow. Cysteine 
residues involved in disulfide bridges are connected. The two cysteine residues responsible 
for trimer formation are boxed in red. The free cysteines are underlined. Sequences were 
obtained from Uniprot. Multiple sequence alignment was performed using Cobalt 
Constraint-based Multiple Alignment Tool (NCBI) (25, 26). 
  





Figure 6. Model of the trimeric peroxidase domain of peroxidasin. The model of the 
peroxidase domain of peroxidasin was constructed with SWISS model using the structure 
of goat lactoperoxidase (PDB code 2R5L) as a template. It comprises the amino acids 
Ala718-Asp1314 of peroxidasin with addition of Cys1315 at the C-terminus. The heme is 
shown in the active site. Blue arrows mark the disulfide bonds between monomers, black 
arrows mark the access to the active site (26). 
  





Figure 7. Evolution of animal peroxidases. Peroxidasin is proposed to be the ancestral 
animal heme peroxidase in Cnidaria, which extended into invertebrates and vertebrates 
with addition of Ig and VWC domains. TPO arose from peroxidasin as a result of gene 
duplication, deletion of non-catalytic domains and fusion with a transmembrane (TM) 









Since its discovery in Drosophila, peroxidasin was thought to have extracellular and 
intracellular functions. The uncommon combination of the non-catalytic domains 
with the active peroxidase domain, and the constitutive secretion of peroxidasin led 
to the hypothesis that peroxidasin is involved in cross-linking of the extracellular 
matrix (15). In addition, peroxidasin was proposed to act intracellularly in the 
phagocytic breakdown of apoptotic cells. The mechanism of activity was unclear, 
but Nelson and colleagues postulated that it might be similar to the cross-linking of 
tyrosine residues by other peroxidases (Figure 8), such as ovoperoxidase in sea 
urchin which forms dityrosine bridges to stabilise the ECM (30). Peroxidasin 
purified from Drosophila exhibited peroxidase activity, with oxidative iodination of 
proteins and formation of dityrosine (15). The heme poison azide inhibited the 
enzymatic activity of peroxidasin, providing further evidence that this protein is 
indeed a heme peroxidase. A lysate of peroxidasin-transfected cells was also found 
to oxidise Amplex red to the fluorescent resorufin, strengthening the evidence that 
peroxidasin has peroxidase activity (22).  
 
Figure 8. Formation of dityrosine by peroxidases. Peroxidases can oxidise tyrosine in 
two sequential one-electron oxidation steps to form radicals that dimerise into dityrosine. 
  




Gotenstein et al. reported an essential biological function of peroxidasin 2 in C. 
elegans embryonic morphogenesis (31). They showed that peroxidasin 2 promotes 
elongation and muscle attachment at specific embryonic developmental stages, as 
well as axon regrowth following injury in adult worms. Mutations in the pxn-2 gene 
caused abnormal epidermal morphology, some of which were lethal. A later study 
showed that peroxidasin 1 was also involved in the structural integrity of ECM and 
neuronal guidance during C. elegans development (32). The knockout of 
peroxidasin gene in mouse embryonic fibroblasts and Drosophila resulted in a 
disorganised network of collagen IV, which further supported the hypothesised 
biological function of peroxidasin in cross-linking ECM (24, 33). Peroxidasin was 
found in the epithelial layers of the cornea and lens. Evidence from human case 
studies suggested that peroxidasin is essential for the normal development of the 
eyes, and plays a role in supporting the structure of the cornea and lens, and 
potentially protecting the eye against oxidative damage (34). All of this data is 
consistent with the proposed role of peroxidasin in the biogenesis and maintenance 
of the ECM. 
Our understanding of the physiological function of peroxidasin in mammals gained 
a leap forward when Bhave et al. provided the first in vitro evidence that 
peroxidasin catalyses the formation of the sulfilimine bond to cross link collagen IV 
in ECM isolated from a mouse epithelial cell line (33). They showed that peroxidasin 
was involved in the cross-linking through the production of hypohalous acids 
(Figure 9). Interestingly, myeloperoxidase and lactoperoxidase were inefficient in 
catalysing the sulfilimine bond formation in collagen IV when overlaid on top of 
isolated uncross-linked ECM (33). Collagen IV isolated from peroxidasin knockout 
mice lacks sulfilimine cross links which are present the wild type (24). Bromide was 
shown to be essential for the peroxidasin-catalysed cross-linking of collagen IV. 
Dietary bromide deficiency resulted in a significant loss of the sulfilimine bond and 
increased lethality in Drosophila (35). 
 
Figure 9. Proposed reaction for the generation of HOBr by peroxidasin. 
 
H2O2 + Br⁻    HOBr + OH⁻ 
Peroxidasin 




The physiological function of peroxidasin as a generator of a powerful oxidant in 
the ECM may not be limited to cross-linking of collagen IV. A study has shown that 
the expression of peroxidasin was upregulated after bacterial infection in the gut of 
mosquito (36). Some studies also suggested an antibacterial activity of peroxidasin 
(37, 38) and a role in redox signalling by interacting with the antioxidant response 
transcription factor Nrf2 (39). Peroxidasin is also suggested to play a role in wound 
repair through cross-linking tyrosine (40). More recently, peroxidasin was shown 
to function in angiogenesis by promoting phosphorylation of different kinases and 
inducing the proangiogenic downstream genes (41). 
1.2.4 Reaction mechanism 
Progress in elucidating the enzymology of peroxidasin is limited by technical 
challenges to purify or express the native full-length trimeric enzyme, with heme 
incorporation and enzymatic activity. Researchers in Obinger’s laboratory in 
Vienna have successfully produced an active truncated monomeric variant of 
peroxidasin containing only the peroxidase and the four Ig domains with the heme 
prosthetic group covalently attached. Kinetic studies using this construct (hsPxd01-
con4) provided very useful insights into peroxidasin substrate specificity and 
mechanism of catalysis (13, 25).  
The spectral features of this monomeric construct (hsPxd01-con4) are very similar 
to those of lactoperoxidase (Figure 10), which reflects the similarity in amino acid 
sequence and active site environment. Spectroelectrochemical analysis of hsPxd01-
con4 gave a standard reduction E’° [Fe(III)/Fe(II)] of -128 mV, second to 
myeloperoxidase in oxidising power (Table 2).  





Figure 10. Spectral features of peroxidasin. UV-visible spectra of hsPxd01-con4 (green) 
and lactoperoxidase (grey) in 100 mM phosphate buffer, pH 7.4. Figure from (13). 
 
Table 2. Reduction potentials for mammalian peroxidases. Fe(III)/Fe(II) reduction 
potential for hsPxd01-con4 (in 100 mM phosphate buffer, pH 7.4), for MPO, EPO and LPO 
(in 10 mM phosphate buffer, pH 7.0). 
 MPO hsPxd01-con4 EPO LPO 
Fe(III)/Fe(II) +5 (42)  -128 (13) -176 (43) -183 (43) 
 
These studies demonstrated that hydrogen peroxide efficiently oxidises the native 
peroxidasin (ferric) to the redox active compound I (oxyiron(IV)). The catalytic 
cycle of peroxidasin starts when the native enzyme in the ferric state reacts with 
hydrogen peroxide to form compound I with the oxoiron(IV) state, which increases 
its oxidising power: 
Ferric enzyme [Fe(III)] + H2O2  Compound I [•+Fe(IV=O)] + H2O 
Reaction 1 
The apparent rate constant (kapp) for this bimolecular reaction is within the same 
range as other mammalian heme peroxidases (1.1 – 5.6 ⨯107 M-1 s-1). The conserved 
distal His and Arg aid with the heterolytic cleavage of hydrogen peroxide (44).  




Similar to other mammalian heme peroxidases, a high molar excess of hydrogen 
peroxide converts compound II to the inactive compound III (13), (reaction 2): 
Compound II [Fe(IV=O)] + H2O2  Compound III [Fe(II)-O2] ↔ [Fe(III)-O2⁻] + H2O 
Reaction 2 
Compound I can enter the peroxidation cycle (Figure 2), which involves two 
consequential one-electron oxidation steps of an organic substrate (AH), producing 
radicals (AH) (Reactions 3 and 4): 
Compound I [+Fe(IV=O)]+ AH  Compound II [Fe(IV=O)] + AH 
Reaction 3 
Compound II [Fe(IV=O)] + AH  Ferric enzyme [Fe(III)] + AH + H2O 
Reaction 4 
Compound I can also enter the halogenation cycle, which involves one-step two 
electron oxidation of a halide (X⁻) producing a hypohalous acid (HOX) (Reaction 5): 
Compound I [+Fe(IV=O)] + X⁻ + H+  Ferric enzyme [Fe(III)] + HOX 
Reaction 5 
Bromide reacts with compound I and converts it back to the ferric state (rate 
5.6⨯106 M-1 s-1 at pH 7.4). It therefore outperforms MPO and LPO but not EPO 
(Table 1) (13). Thiocyanate and iodide are also highly efficient in converting 
compound I of peroxidasin to the ferric state (rates 1.83 and 1.68 ⨯107 M-1 s-1 at pH 
7.4). Interestingly, high concentrations of iodide (10 mM) inhibited the sulfilimine 
bond formation in collagen IV, possibly due to acting as a competitive substrate 
(33).  




Peroxidasin was initially reported to moderately oxidise chloride as well (33, 45). 
Until then, this was thought to be an exceptional ability of MPO, due to the unique 
sulfonium linkage between the heme and Met residue in its active site. The pre-
steady state kinetic study using the recombinant monomeric construct (hsPxd01-
con4) showed that chloride cannot reduce compound I of peroxidasin (13). The 
oxidation activity that was observed in the earlier studies was probably due to 
residual bromide contamination in chloride (33, 35, 45). Furthermore, the 
production of hypohalous acids by peroxidasin was determined by 
tetramethylbenzidine (TMB) assay (33). This assay detects HOCl and HOBr by 
converting them to the respective chloramine and bromamine. It distinguishes the 
derived species by the addition of iodide (46), but does not provide a definitive 
chemical identification of the oxidant produced.  
Recent work from the Obinger group shows that peroxidasin can react with 
endogenous peroxidase substrates (urate, ascorbate, nitrite, serotonin and 
tyrosine) by one-electron oxidations to generate their respective radicals. These 
substrates reduced compound I to compound II (rates range between 104 – 105 M-1 
s-1). Reduction of compound II to the resting enzyme by these substrates is 
approximately 100 fold slower (47).  
One of the puzzling questions regarding peroxidasin activity, is the source of 
hydrogen peroxide, the necessary co-substrate to initiate the catalytic cycle. In the 
case of other peroxidases, NADPH-oxidases (Nox or Duox enzymes) are the sources 
of H2O2 (48). However, a recent study found that Nox knockout and hypoxia had no 
effect on peroxidasin-catalysed cross-linking of collagen IV (49). One possibility is 
that intracellular H2O2 diffuses to the ECM where peroxidasin can use it (50), as 
mitochondria are often located at the basolateral side of epithelial cells close to the 
basement membrane, but that hypothesis is yet to be tested.  
  




1.2.5 Role in disease 
An increasing amount of evidence implicates peroxidasin in a number of 
pathologies. Loss of function of peroxidasin is detrimental to Drosophila and C. 
elegans because of compromised integrity of the basement membrane (15, 31-33, 
51). Peroxidasin mutation is not lethal in mice or humans, but causes disruption to 
the basement membrane, especially in the eye lens and cornea (52). Mutations in 
peroxidasin lead to inherited eye disorders, including microphthalmia (small eye), 
anterior segment dysgenesis, congenital cataract and developmental glaucoma in 
humans (34, 52-54). A missense mutation was found in patients with recessively 
inherited congenital cataract-microcornea with corneal opacity. In this mutation, a 
conserved arginine in the peroxidase domain is changed to a cysteine residue, 
altering the structure and function of peroxidasin and leading to the pathology (34).  
Peroxidasin (termed VPO1 in these studies) was found to promote oxidative stress 
in the cardiovascular system and contribute to the oxidation of low density 
lipoprotein and endothelial dysfunction (55-62). Other studies proposed the 
involvement of peroxidasin in mediating oxidative injury following ischemia-
reperfusion (63), and showed that its inhibition alleviates cardiac dysfunction and 
ischemia-reperfusion induced apoptosis (64, 65). Expression of peroxidasin was 
upregulated in a rat model of hypertension, suggesting its involvement in the 
regulation of vascular smooth muscle cell proliferation and possible contribution to 
vascular remodelling in hypertension (66, 67).  
Peroxidasin is also implicated in renal and pulmonary pathologies. It contributes to 
renal inflammation and fibrosis in a mouse model of chronic kidney disease (22, 
68). Inhibitory anti-peroxidasin antibodies were found in the sera of patients with 
pulmonary-renal syndromes, in samples taken before and during active disease, 
suggesting a role in the pathogenesis (69).  
Increasing evidence in recent years shows altered expression of peroxidasin in 
various types of cancer including melanoma, acute myeloid leukemia, metastatic 
glioblastoma, breast, renal, colon and ovarian cancers (70-76). Upregulation of 




peroxidasin expression in prostate cancer promotes disease progression by altering 
the redox environment and decreasing cell apoptosis (77). Peroxidasin is involved 
in epithelial-mesenchymal transition, a process in which cancers acquire an 
invasive phenotype (78). Gene expression profiling in fourteen types of cancer 
demonstrates that the peroxidasin gene plays a key role in the heme-oxygenase-1-
dependent cell adhesion and invasion in neoplastic cells (79). Silencing the 
peroxidasin gene abolished the adhesion-promoting effect of heme oxygenase-1 in 
two melanoma cell lines. The human homolog of peroxidasin found in colorectal 
cancer (PRG2) was proposed to have an intracellular role in producing reactive 
oxidants that induce apoptosis by inactivating the p53 tumour suppressor protein 
(16).  
In summary, peroxidasin plays a role in a multitude of diseases by different 
mechanisms that include altering the redox homeostasis, changing ECM properties 
and promoting fibrosis, angiogenesis and cancer metastasis. 
  




1.3. Biological oxidants 
Oxidants are a wide class of molecules that remove one or two electrons from other 
molecules to become reduced. They include radical and non-radical reactive oxygen 
species (ROS), reactive nitrogen species (RNS), and halogenated species (Figure 
11). Biological oxidants are produced constantly as part of normal physiological 
processes such as respiration (80). There are endogenous sources of ROS (e.g. 
mitochondria, NADPH oxidases) and exogenous sources (e.g. radiation, xenobiotics) 
(81).  
Regulated production of ROS plays essential roles in signalling pathways, cellular 
differentiation, immune response and responding to growth hormones (82, 83) 
(Figure 12). Dysregulated ROS production can distort the redox balance, leading to 
oxidative stress, which can have deleterious effects especially in chronic 
inflammatory conditions (83).  
Alongside oxidants, there are complex protective mechanisms that include 
antioxidant enzymes (e.g. catalase, superoxide dismutase, peroxiredoxins), and low 
molecular weight antioxidant compounds (e.g. glutathione, ascorbate, tocopherols) 
(84, 85). These antioxidant systems counteract the oxidative burden and maintain 
steady-state redox homeostasis. Oxidative stress occurs when antioxidant systems 
are overwhelmed by oxidants. 
Oxidants are not made equal in their oxidative power (86). Similarly, antioxidants 
differ in their reactivities with oxidants. Appropriate attention should be given to 
each individual case of oxidant and antioxidant to assess their contribution to 
physiological and pathological processes. For relevance to the research topic, I will 
focus here on reactive halogen species and their biological reactions. 
  





Figure 11. Major types of biological oxidants and some examples. (81). 
 
 
Figure 12. Sources and physiological functions of biological oxidants. There are 
endogenous and exogenous sources of ROS. Redox homeostasis is important for normal 
physiological processes, which can be impaired under oxidative stress. NOX, NADPH 
oxidases, CYP, cytochrome P450, Cat, catalase, SOD, superoxide dismutases, GPx, 
glutathione peroxidase, GSH, glutathione (84).   




1.3.1 Reactive halogen species 
Cytotoxic (pseudo)hypohalous acids are produced by the reactions of hydrogen 
peroxide with halide ions (Cl⁻, Br⁻ and I⁻) and the pseudohalide SCN⁻, which are 
catalysed by mammalian heme peroxidases (87). Reactive halogen species have 
diverse biological functions like antimicrobial defence, hormone biosynthesis and 
consolidation of ECM. They can also cause extensive damage to host tissues, which 
contributes to the aetiology and progression of inflammatory diseases (12, 88). 
Hypohalous acids differ in their oxidising power (HOCl > HOBr > HOSCN) and rates 
of reactions with different biological targets (14). They are highly reactive with 
sulfur-containing compounds (e.g. methionine, cysteine and glutathione), and less 
so with amines (e.g., N-terminus and the side chains of lysine and arginine), 
aromatic compounds (e.g., tyrosine and tryptophan), double bonds (e.g., fatty acids 
and cholesterol) and water-soluble antioxidants (e.g., urate and ascorbate) (5, 89-
92). It is essential to keep in mind that the rates of reactions of HOCl and HOBr can 
vary substantially (Figure 13). The rates of reactions of HOCl with Met and Cys are 
10-fold faster than those for HOBr. Conversely, HOBr reacts with amines and double 
bonds faster than HOCl (93). Halohydrins form on phospholipids at lower 
concentrations of HOBr than HOCl (94, 95). With the exception of ascorbate, 
antioxidants react faster with HOBr than with HOCl. HOCl is a stronger two-electron 
oxidant (Table 3) (96), but HOBr is a more powerful electrophile and hence a better 
halogenating agent (97). These are important considerations when studying the 
hypohalous acid-mediated oxidative modifications and their roles in different 
pathologies. 
The reactions of HOCl and HOBr with primary amines form the respective mono- 
and dichloramines and bromamines (Equations 1 and 2) (98, 99). They retain some 
of the oxidising power and selectivity of the original oxidants. They can be highly 
abundant, and therefore key mediators of oxidative modifications (83).  
RNH2 + HOX  RNHX + H2O (X=Cl, Br)  Equation 1 
RNHX + HOX  RNX2 + H2O    Equation 2 





Figure 13. Reactions of HOCl and HOBr. Summary of second-order rate constants for the 
reactions of HOCl and HOBr with different amino acids, antioxidants and scavengers on a 
log scale. Most of the rate constants were measured at physiological pH at 22°C. S-S, 
disulfide bond, α-NH2, terminal amine, BB, backbone amides. The rate constant for the 
reaction of HOBr with GSH* is shown as that measured for N-acetylcysteine. (5, 81, 87, 92, 
93, 96, 100, 101). 
  




At physiological pH (7.4), hypohalous acids exist in equilibrium with their anions 
(HOCl/⁻OCl, HOBr/⁻OBr, HOSCN/⁻OSCN). Their pKa values vary substantially and 
consequently the major active species will be different for each of them at 
physiological pH (Table 3) (14). The properties and reactivity of hypohalous acids 
can be significantly altered by slight variations in pH, especially cell permeability as 
they become more membrane permeable when they are protonated (14). 
Therefore, special attention should be given to reaction conditions in kinetic 
studies.  
Table 3. Properties of HOCl, HOBr, and HOSCN. Reduction potentials and pKa values for 
hypochlorous acid (HOCl), hypobromous acid (HOBr) and hypothiocyanous acid (HOSCN) 
(14, 96, 102, 103).  
 HOCl HOBr HOSCN 
E° (V) 1.28 1.13 0.56 
pKa 7.59 8.7 5.3 
  




1.4. Protein oxidation 
Biomolecules are constantly exposed to oxidants produced as part of normal 
physiological processes. Proteins are major targets for oxidants, because of their 
abundance and the high reaction rates of oxidants with amino acid side chains. 
Protein oxidation can be reversible, like disulfide bond formation and S-
nitrosylation, or irreversible, like oxidation of aromatic amino acid side chains. 
Oxidative modifications of proteins are often regarded as collateral damage. While 
this is true in a lot of the cases, protein oxidation can be deliberate and serve a 
particular function, such as redox-regulated intracellular and intercellular 
signalling. For example, oxidation and reduction of thiol groups to activate 
peroxiredoxins and caspases (104). Another example of a deliberate oxidative 
modification is the cross-linking of collagen IV, which is explained in more detail in 
Section 1.5.2. 
Nonetheless, oxidative damage occurs, despite multiple antioxidant systems and 
prevention and repair mechanisms. This is especially the case in chronic 
inflammation, deterioration in enzyme efficiency and accumulation of damage with 
aging (84). Oxidative damage can affect DNA, proteins, carbohydrates and lipids 
(104). Protein oxidative damage can impair the structure and function of enzymes, 
and interfere with the function of receptors, transport proteins and antibodies 
(104). For example, oxidative damage to DNA polymerase can compromise the 
fidelity in DNA replication (104). Oxidised proteins can be immunogenic causing 
autoimmune diseases, such as rheumatoid arthritis (12, 105). Accumulation of 
oxidatively damaged proteins in brain tissues is one of the hallmarks of Alzheimer’s 
diseases (106-108). Oxidative damage to fibronectin causes cross-linking of the 
protein, increases its susceptibility to proteolysis and impairs its functions (109, 
110). Hypohalous acids mediated cross-linking of membrane proteins leads to lysis 
of red blood cells (111). These examples highlight how oxidative damage is 
involved, as a cause or a consequence, in a raft of diseases.  




In the following section, I will focus on two amino acids that are major targets of 
oxidants and are used as biomarkers for oxidative modifications. 
1.4.1 Methionine 
The sulfur of methionine is easily oxidised by one- or two-electron oxidants. 
Oxidation of methionine produces methionine sulfoxide (Met-O), sulfone and 
dehydromethionine (Figure 14) (108, 112-114). Methionine sulfoxide is more 
hydrophilic than methionine, which can alter protein structure and lead to loss or 
gain of function (104). The high reactivity of methionine makes it a good 
endogenous anti-oxidant because of its ability to scavenge oxidants and protect 
other key amino acids (115). Methionine sulfoxide can be repaired by methionine 
sulfoxide reductases (116). This reversibility can be used as a switch to activate and 
inactivate proteins (104). However, oxidised methionine can accumulate with aging 
and in inflammatory diseases, especially in collagens of long-lived tissues, such as 
the skin and eye (117, 118).  
 
 
Figure 14. Chemical structures of methionine and its oxidation products. 
  





The aromatic ring of tyrosine is a target for oxidative modifications by different 
pathways (Figure 15). Halogenated tyrosines are minor products but used widely 
as specific, quantifiable biomarkers of hypohalous acid mediated damage to 
proteins (119). Chlorotyrosine and bromotyrosine are products of the reactions 
between tyrosine and HOCl and HOBr, respectively. It is important to bear in mind 
that the rates of tyrosine bromination by HOBr is 5000-fold faster than chlorination 
by HOCl (Figure 13) (93, 120). This is a potential pitfall if chlorotyrosine and 
bromotyrosine are used as biomarkers, as it might cause over- or underestimation 
of the oxidative damage by the respective oxidants.  
Tyrosine is also a substrate for peroxidases and can be oxidised directly, producing 
reactive phenoxyl radicals, which can cross-link to form dityrosine (Figure 8) (90, 
121). Nitrotyrosine is another product of tyrosine oxidation (122). Peroxidases can 
oxidise nitrite to nitrogen dioxide (NO2•), which undergoes reactions with the 
phenol of tyrosine forming nitrotyrosine (123, 124). Nitrotyrosine is elevated in 
bronchoalveolar lavage of asthmatic patients (125) and in human atherosclerotic 
lesions (126), due to the activities of human peroxidases. Nitrotyrosine can also 
arise from oxidation by nitrating species such as peroxynitrite (127). 
Tyrosine residues play key roles in signaling and enzymatic catalysis. Oxidation of 
tyrosine can lead to substantial changes in protein structure and function, such as 
signalling with tyrosine kinase or phosphatase (128). Oxidation products of 
tyrosine can be useful biomarkers for oxidative damage, especially in pathological 
situations. Chlorotyrosine is significantly elevated in human atherosclerotic lesions 
(129, 130). High levels of chlorotyrosine are also found in the sputum and 
bronchoalveolar lavage fluid of patients with cystic fibrosis (131) and in brain 
tissues of patients with Alzheimer’s disease (107). Bromotyrosine is a specific 
biomarker for protein modifications by eosinophil peroxidase in asthmatic patients 
(89, 132). Products of hypohalous acid oxidation are elevated in a multitude of 
diseases such as cystic fibrosis, asthma, cardiovascular diseases and rheumatoid 
arthritis (14, 132-140). 





Figure 15. Tyrosine and some of its oxidation products.  The reaction of HOBr with 
tyrosine generates 3-bromotyrosine and 3, 5-dibromotyrosine. HOCl reacts with tyrosine 
to produced 3-chlorotyrosine and 3, 5-dichlorotyrosine. Peroxidases can oxidise tyrosine 
directly to produce tyrosyl radicals that can dimerise into dityrosine. Peroxidases can also 
oxidise nitrite (NO2⁻) to generate nitrogen dioxide radical (NO2) which reacts with tyrosyl 
radical to form 3-nitrotyrosine (119, 141, 142). R= amino acid backbone. 
  




1.5. The extracellular matrix and collagen IV 
The extracellular matrix is a complex multi-component network of highly cross-
linked insoluble material. The major classes of ECM constituents are fibrous 
proteins (e.g. collagens and elastin) and glycoproteins (e.g. fibronectin, laminin and 
proteoglycans) (143). The evolution of ECM was a crucial event for the development 
of multicellular life. ECM provides the structural platform for cells to adhere to, 
polarise, proliferate, communicate and migrate (144, 145). It also regulates 
hydration and the pH of the microenvironment and the response to growth factors. 
Because of its essential and diverse functions, ECM abnormalities can cause 
dysregulated cell behavior and lead to the progression of many diseases, such as 
tissue fibrosis and cancers (146-148). 
Basement membrane (BM) is a specialised form of ECM that lies between epithelial 
cell layers and a variety of tissues (Figure 16) (149). For most epithelial cells, the 
BM is the only physical contact with the rest of the body. For example, epithelial 
cells in the lungs and kidneys are only in contact with the BM, and air and urine, 
respectively. BM also surrounds endothelial cells of blood vessels, the outer layer of 
organs, muscle fibers, fat cells and nerve cells. All types of BM consist of laminin, 
nidogen, perlecan, agrin and collagen IV (Figure 17). In addition to the ECM 
functions above, BM maintains the structural integrity and homeostasis for cells, 
filters macromolecules and compartmentalises tissues (143).  
  





Figure 16. Histological identification of basement membrane. Arrows point to 
basement membrane around tubules of a mouse kidney paraffin section stained with 
Periodic acid-Schiff. Figure from (143). 
 
 
Figure 17. Schematic model of the basement membrane. The BM lies between the 
epithelial cells and interstitial extracellular matrix (IECM). It consists of two layers of 
laminin and collagen IV which are interconnected by perlecan and nidogen. Figure from 
(150) with modifications. 
 




1.5.1 Collagen IV 
Collagen IV is a major constituent of the basement membrane (accounts for ~50 % 
of its structural components), and is common to all metazoans, from sponges to 
primates (151). Collagen IV networks provide tensile mechanical strength and act 
as scaffolds for the interaction of BM components. These interactions are essential 
for tissue genesis, cell differentiation, morphogenesis, adhesion, migration, 
proliferation, homeostasis and signalling (149). Collagen IV is the binding partner 
for various types of cells including keratinocytes (152), hepatocytes (153), and 
pancreatic cells (154).  
The collagen IV molecule contains three domains; a short domain at the amino 
terminal (7S), a major collagenous domain that contains Gly-Xaa-Yaa triplet repeats 
(X, Y= any amino acid), and a non-collagenous domain (NC1 or NCD) at the carboxy 
terminal (Figure 18) (155, 156). There are six homologous but genetically distinct 
chains (α1- α6) that are differentially expressed in various tissues and 
developmental stages. Of the several possible combinations, only three 
heterotrimers occur; α1α1α2, α3α4α5, and α5α5α6. (149). Collagen IV is subject to 
post-translational modifications, such as oligomerisation, glycosylation of lysine 
residues, hydroxylation of lysine and proline residues and formation of interchain 
disulfide bonds between cysteine residues (149, 157). Proteolytic release of the 
NCD of collagen IV (and other types of collagen) modulates cell migration, 
proliferation and survival (158). These modifications are vital for proper folding 
and functioning of collagen IV. 
Oligomerisation of collagen IV is a complex process with intracellular and 
extracellular steps (Figure 18). Inside the cell, three chains assemble into a 400-
nm-long triple helical protomer. With the help of chaperone proteins, collagen IV 
heterotrimers are secreted into the ECM where they assemble into a 
supramolecular polygonal chicken-wire like network (159). The higher chloride 
concentration outside the cell activates the assembly of two protomers at the NCD 
with intermolecular electrostatic interaction (160). These interactions are 




enzymatically stabilised by sulfur-nitrogen cross links at the NCD (33), and 
aldehyde cross links at the 7S domain (161). 
 
Figure 18. Collagen IV structure and assembly. The different types of collagen IV 
monomers (a1-6) with 7S domain, central collagen domain (~1400 AAs long) and the NCD 
(~230 AAs). Intracellularly, three monomers assemble into heterotrimers by 
intermolecular disulfide bonds at the central collagen domain. Extracellularly, two trimers 
join at the NCD forming an interface hexamer at the C-terminus, and four triple helical 7S 
domains at the N-terminus forming supramolecular structures. Figure from (162). 
  




1.5.2 The sulfilimine bond 
The chemical nature of the cross link at the NCD intersection was a subject of 
controversy. The bond was hypothesised to be a disulfide bridge (163, 164) or 
covalent sulfur-nitrogen bond between methionine and lysine (165, 166). 
Subsequent mass spectrometric evidence led to speculation that the nature of the 
bond was an S-hydroxylysyl-methionine cross link (167). Finally, this sulfur-
centered bond was characterised by mass spectrometry and nuclear magnetic 
resonance as a sulfilimine link, a covalent double bond between the sulfur of Met93 
and the amine of the juxtaposed Hyl211 located at the NCD interfaces of two 
protomers (168). One or two sulfilimine bonds can form between two NCD 
molecules, with a maximum of six cross links at the trimer-trimer interface of the 
hexamer (35). The presence of the sulfilimine cross link modulates mechanical 
resilience and stiffness of the basement membrane (169).  
This peculiar cross link occurred over 500 million years ago, and is conserved 
throughout the Eumetazoa subkingdom (170). The occurrence of nitrogen-sulfur 
bonds in biology is rare. The sulfilimine bond is even rarer, with collagen IV being 
the only known biomolecule to contain this unusual bond (171). Sulfilimine bonds 
were reported to form intra- and intermolecular cross links in peptides treated with 
hypohalous acids in vitro (172). The sulfur-nitrogen bond in the sulfilimine bond is 
similar to that in dehydromethionine (Figure 14), one of the products of the 
reaction between methionine and hypobromous acid (114). 
The chemical mechanism of sulfilimine bond formation is still not clear. It is 
proposed to proceed through bromide transfer from HOBr to Met93 forming a 
bromosulfonium cation intermediate, followed by a nucleophilic attack by the 
amine of Hyl211 forming the intermolecular sulfur-nitrogen double bond (Figure 
19). Reagent HOBr efficiently generated the sulfilimine cross link in isolated NCD of 
collagen IV, but HOCl was inefficient (35). When HOCl was reacted with the NCD, 
formation of methionine sulfoxide increased as identified by mass spectrometry. 
Pre-treatment of NCD with reagent HOCl inhibited the formation of the cross link 
by HOBr, indicating that methionine sulfoxide is a dead-end intermediate which 




does not react with hydroxylysine to form the sulfilimine bond. This explains the 
selectivity for bromide in generating this bond. 
 
Figure 19. Chemical mechanism for the formation of the sulfilimine cross link in 
collagen IV. The proposed mechanism of sulfilimine bond formation by HOBr involves a 
bromosulfonium ion intermediate on Met that reacts with the amine of Hyl yielding a 
sulfilimine link as the primary product. The chlorosulfonium ion thermodynamically 
favours the reaction with water which yields sulfoxide as the primary product (35, 172). 
Bold arrows indicate major reactions.  
  




1.5.3 Pathologies of collagen IV and the ECM 
Collagen IV malfunction is implicated in several genetic and acquired diseases. 
Abnormalities in collagen IV destabilise the basement membranes of many organs 
and impair tissue function, particularly the kidney, due to the key role of basement 
membrane in glomerulus structure and function (149, 162, 173). Some mutations 
in collagen IV genes are embryonically lethal, while others lead to human diseases 
varying in severity, like Alport’s syndrome, Goodpasture autoimmune disease, 
diabetic nephropathy and angiopathy (174).  
Alport’s syndrome is a genetic disease that causes inflammation of renal glomeruli 
and is associated with deafness. Mutation in any of the collagen IV (a3, a4 or a5) 
genes leads to formation of abnormal collagen IV chains, and subsequently 
formation of defective glomerular basement membranes (175). Symptoms such as 
blood in urine begin in childhood and renal failure develops by adolescence (176). 
Goodpasture syndrome is an autoimmune disease characterised by 
glomerulonephritis and lung haemorrhage that can be detrimental if not treated 
early (162). The disease is caused by pathogenic circulating antibodies to 
a3(IV)NCD, which are predominant in the kidney glomerular BM and the lung 
alveolar BM (177). The sulfilimine cross link provides protection against the 
collagen IV antigen of Goodpasture disease (173). 
Collagen IV also plays a role in tumour pathogenesis and malignancy, possibly 
through regulating angiogenesis (148). It is the binding substrate for many cancer 
cells, including melanoma (178), breast (179) and prostate (180), and it 
accumulates in the tumour interstitium (148). 
The extracellular matrix is ubiquitous and has essential and diverse functions that 
affect cells, tissues and organs. Therefore, ECM abnormality can cause dysregulated 
cell-matrix interactions and lead to progression of many diseases, such as tissue 
fibrosis, muscular dystrophy and cancers (146-148, 181).  




Fibrosis is a heterogeneous disorder that affects connective tissues in all organs, 
especially the heart, liver and kidney (182). It usually results from a defective 
wound healing process. Fibroblasts normally respond to injury signals and 
differentiate into myofibroblasts, which synthesise matrix material to repair the 
damaged ECM. When this processes is disrupted, fibrotic tissues can develop and 
lead to disorganised, stiff and dysfunctional ECM, which sets off a cascade of 
downstream effects and causes a multitude of diseases in the affected organs (183). 
For example, fibrosis of the heart leads to diastolic heart failure (184).  
Damage to ECM can be mediated by oxidants. In contrast to inside the cell, the 
extracellular space is deficient in antioxidant defense mechanisms (121). Moreover, 
ECM components turn over slowly with limited mechanisms for repair or removal 
of damaged proteins. Oxidative modification of ECM can alter protein structure and 
function, leading to changes in solubility and aggregation, rigidity, permeability, 
signaling and ligand binding. Oxidative damage to the ECM is associated with many 
pathologies, including cardiovascular, lung and kidney diseases (12). A significant 
number of studies point to the role of myeloperoxidase as the source of oxidants at 
inflammatory sites (6, 131, 185, 186). Hypohalous acids increase post-translational 
modifications of renal tissues and ECM proteins, particularly collagen IV in 
experimental diabetic nephropathy (187). More recently peroxidasin has emerged 
as a contributor to the damage in pulmonary and renal inflammation, and fibrosis 
(22, 68, 69), as reviewed earlier in Section 1.2.5. The proposed mechanisms of 
promoting these pathologies are related to oxidative modification of tissues and 
destabilisation of the ECM. 
  




1.6. Summary and aims 
Peroxidasin is a rising star in the field of human peroxidases. It is an unusual 
peroxidase in its structure as it contains non-catalytic domains in addition to the 
catalytic peroxidase domain. It catalyses the formation of an unusual sulfilimine 
cross link that is only found in collagen IV, in a rare example of an anabolic function 
of hypobromous acid, a powerful oxidant and destructive bactericide. This 
physiological function of peroxidasin was unravelled in 2012, eighteen years after 
the discovery of the protein. Other functions have been suggested or demonstrated, 
such as activation of angiogenic signalling pathways (41). There has been increasing 
interest in studying peroxidasin and elucidating its enzymology (Figure 20). 
However, there are more questions than answers about its activity and roles in 
physiology and pathology. The inherent physical and chemical properties of 
peroxidasin make it difficult to purify or express in an active form that would allow 
studying it in an isolated system. There is increasing evidence that implicates 
peroxidasin in a number of diseases, which suggests it has physiological and 
pathological functions beyond cross-linking collagen IV. It also opens up many 
questions about the regulation of peroxidasin activity as a generator of a powerful 
oxidant in the ECM. 
 
Figure 20. The number of publications on peroxidasin since its discovery in 1994. 
Web of science (10 Dec 2019). 
  




In this research project, I aim to explore some of the questions surrounding the 
enzymology of peroxidasin. In particular, my goals in this thesis are to: 
 Establish a model system to study the activity of peroxidasin in the ECM. 
 Investigate peroxidasin substrate requirement for cross-linking collagen IV. 
 Investigate the production of HOBr by peroxidasin in the ECM. 
 Study the effects of substrates and inhibitors of other peroxidases on the 
activity of peroxidasin. 
 Develop methods to measure biomarkers of protein oxidation, namely 
methionine sulfoxide, 3-bromotyrosine and 3-nitrotyrosine with application 
to ECM. 
 Explore reactions of HOBr beyond catalysing the formation of the sulfilimine 
bond in collagen IV. 
 
  
Chapter 2 Materials and Methods 
2.1 Materials 
2.1.1 Chemicals 
All chemicals used in this project were of analytical purity grade. The chemicals 
used and manufacturers are listed in Table 4. 
Table 4. List of chemicals used in this thesis. 
Item Manufacturer/Supplier 
13C6 Tyrosine Isotec 
3-isobutyl-2-thioxo-7H-purin-6-one (TX1) Gift from AstraZeneca 
4-aminobenzoic acid hydrazide (ABAH) Fluka 
Acetaminophen Sigma-Aldrich 
Acetic acid Univar Solutions 
Acetonitrile Scharlau 
Acrylamide:bis solution 37.5:1 Bio-Rad 
Ammonium ferrous sulfate Baker 
Ammonium Persulfate (APS) Sigma-Aldrich 
AmplexTM UltraRed Reagent Invitrogen 
Bovine serum albumin (BSA) Gibco Life Technologies 
Catalase  Sigma-Aldrich 
Collagenase  Worthington Biochemical 
Complete™ Protease inhibitor cocktail  Roche 
Coomassie Brilliant Blue R-250 ThermoFisher 
Diethylaminoethyl (DEAE) Sepahrose GE Life Sciences 
Dithiothreitol (DTT) Sigma-Aldrich 
Ethanol Merck 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich 
Formic acid Merck 
Glutathione (GSH) Sigma-Aldrich 
Glycerol Merck 





Hybond-P™ polyvinylidene fluoride (PVDF) membrane  Amersham Biosciences 
Hydrochloric acid (HCl) Fisher Chemicals 
Hydrogen peroxide 30 % analytical grade Lab Serv. 
Iodoacetamide (IAM) Sigma 
L-methionine Sigma-Aldrich 
Methane sulfonic acid (MSA) Sigma-Aldrich 
Methionine Sigma-Aldrich 
NADH Sigma-Aldrich 
Phloroglucinol  Sigma-Aldrich 
Pierce ECL™ Plus Western Blotting Substrate #32132 Thermo Scientific 
Potassium bromide BDH Laboratories 
Precision Plus Protein™ Dual Color Standards Bio-Rad 
Pronase from Streptomyces griseus Sigma-Aldrich 
R19-S  FutureChem Co. 
Sodium ascorbate Sigma-Aldrich 
Sodium azide Sigma-Aldrich 
Sodium chloride Labserv 
Sodium deoxycholate Sigma-Aldrich 
Sodium dodecyl sulfate (SDS) BDH 
Sodium hypochlorite (Janola) Pental Products 
Sodium nitrite Fisons 
Sodium thiocyanate Sigma-Aldrich 
Sorbitol Sigma-Aldrich 
Sulfuric acid Merck 
Taurine Sigma-Aldrich 
Tetramethylethylenediamine (TEMED) Sigma-Aldrich 
Thiodipropionic acid Sigma-Aldrich 
Tris Base Roche 




Uric acid Sigma-Aldrich 
Xylenol Orange Sigma-Aldrich 
  




2.1.2 Cell culture media 
Cell culture media, fetal bovine serum (FBS), antibiotics (Penicillin-Streptomycin) 
and TrypLE® Express are all from Gibco Life Technologies. 
2.1.3 Antibodies 
Antibodies used for western blotting are listed in Table 5. 
Table 5. Antibodies and manufacturers.  
Antibodies 
Rabbit polyclonal anti-catalase. Abcam 
Rabbit polyclonal anti-peroxidasin. Gift from Miklos Geizst, Budapest, Hungary 
Goat anti-rabbit HRP. Sigma 
  
2.1.4 Equipment and Software 
Equipment and software used in this project are listed in Table 6. 
Table 6. Equipment and software used in this project.  
Equipment 
Direct Detect® Infrared Spectrometer Merck Millipore 
Heracell™ 150i CO2 incubation Thermo Scientific 
NanoDrop™ Lite Spectrophotometer Thermo Scientific 
NanoPhotometer® Spectrophotometer IMPLEN 
SpectraMax 190 Microplate Reader Molecular Devices 
Spectrophotometer 8453 Agilent 
Spectrophotometric plate Reader Varioskan Flash Thermo Scientific 
Ultrasonic homogeniser Sonic Ruptor 400 OMNI-INC 
UVITEC Cambridge Gel documentation system UVITEC Cambridge 
  





ChemDraw Prime V17.0.0.206 (121) PerkinElmer Informatics, Inc 
Excel MS Office 2010  Microsoft Corporation 
GraphPad Prism V 7.04 GraphPad Software, Inc. 
Skan It RE for Varioskan Flash 2.4.3 (Research Edition) Thermo Scientific 
SoftMax Pro 5.3 Molecular Devices 
UVITEC Alliance 4.7 UVITEC Cambridge 
 
2.1.5 General buffers and solutions 
The general buffers and solutions and their compositions are listed in Table 7. 
Table 7. Compositions of general buffers and solutions. 
Buffers 
Phosphate buffered saline (PBS) 140 mM NaCl, 13 mM KCl in 10 mM sodium 
phosphate buffer, pH 7.4. 
Tris buffered saline (TBS) 20 mM Tris-HCl, 140 mM NaCl, pH 7.6. 
Sample buffer 300 mM Tris-base pH 6.8, 25 % glycerol, 10 % (w/v) 
SDS, 0.05 % (w/v) bromophenol blue. 
Electrophoresis running buffer 
(10x top tank) 
25 mM Tris, 192 mM glycine, 0.1 % (w/v) SDS. 
Electrophoresis running buffer 
(lower tank) 
83 mM Tris 
Transfer buffer 25 mM Tris, 192 mM glycine, 15 % (v/v) methanol, 
pH 8.3 
Coomassie staining solution 0.25 % (w/v) Coomassie Blue R-250, 45 % (v/v) 
ethanol, 10 % (v/v) acetic acid  
Destaining solution 45 % (v/v) ethanol, 10 % (v/v) acetic acid) 
 
  





2.2.1 Cell culture 
All cell lines used were available in the cell culture stocks within the Centre for Free 
Radical Research, and were originally obtained from the American Tissue Culture 
Collection (ATCC). Cell types, media and culture properties are shown in Table 8. 
Cell handling was carried out using sterile techniques. All cells were incubated at 
37°C in a humidified environment containing 5 % CO2. Adherent cells were 
passaged when confluent (every four days) using TrypLE®Express to detach cells 
and seeded in new flasks with fresh medium at 1 x 106 cells/ml. Cells were routinely 
tested and found to be mycoplasma free. 
Table 8. Cell lines used in this research project. 
Cell line Type Medium Properties 
MEF Mouse embryonic fibroblasts 
(ATCC® SCRC-1040™) 
DMEM + 10 % FBS +     
1 % pen/strep 
antibiotics + 5 % L-Asn. 
Adherent 
PFHR9 WT Mouse epithelial cells  
(ATCC® CRL-2423™)  
DMEM, 10 % FBS,  
1 % pen/strep 
antibiotics. 
Adherent 
PFHR9 KO  Peroxidasin-knockout mouse 
epithelial cells obtained as a gift 
from Gautam Bhave laboratory, 
Vanderbilt University, Nashville, 
Tennesse, USA. CRISPR-mediated 
Knock-out method is described in 
(27). 
DMEM, 10 % FBS,  









2.2.2 Isolation of the extracellular matrix  
A cell model was used to study peroxidasin in the ECM. Mouse epithelial-like cells 
(PFHR9) deposit appreciable amounts of ECM. The procedure was followed as 
described by Bhave et al. (33). PFHR9 cells were seeded at confluent density in 6-
well, 10 cm or 15 cm plates, and kept in culture with a daily change of medium 
(DMEM + 10 % fetal bovine serum + 1 % penicillin/streptomycin antibiotics) and 
the indicated treatment for 6-8 days. For harvesting, the media was removed and 
the cells were washed twice with 1x PBS. Cells were incubated for 2 minutes in ice 
cold Lysis Buffer (10 mM Tris pH8, 1 mM EDTA, 1 % Sodium deoxycholate, 1x 
Complete® Protease Inhibitor), then scraped with a cell scraper and transferred to 
an Eppendorf tube. The lysate was sonicated with a fine tip probe three to four 
times, ten seconds each until lysate was homogeneous. The lysate was spun at 
20,000 g for 20 min at 4°C, and the supernatant was separated from the pellet. The 
pellet was washed twice in Wash Buffer (1M NaCl, 10 mM Tris pH7.5) with spinning 
at 20,000 g for 10 minutes at 4°C. The ECM pellet was resuspended in PBS with brief 
sonication. Protein concentration was measured using Direct Detect® Infrared 
Spectrometer. The yield of ECM proteins from a 15 cm culture plate after 6-8 days 
was approximately 5 mg. 
2.2.3 Isolation of the non-collagenous domain 
To separate the non-collagenous domain, ECM was first digested with collagenase. 
The isolated ECM was resuspended in digestion buffer (2mg/ml bacterial 
collagenase in 50 mM sodium phosphate pH 7.4) and left overnight at 37°C (188). 
The NCD was purified by anion-exchange chromatography using DEAE resin (189). 
The digest was spun down at 20,000 g for 2 minutes, and the supernatant was mixed 
with an equal volume of DEAE resin (equilibrated in 50 mM Tris pH 7.4) with 
shaking for 1 hour at 4°C. The slurry was spun down at 10,000 g for 2 minutes, and 
the soluble unbound NCD was taken in the supernatant for analysis. The procedure 
is outlined in Figure 21. 




2.2.4 Cross-linking of collagen IV in the decellularised ECM 
Epithelial cells were grown for 6-8 days in the presence of 50 µM phloroglucinol 
(PHG) to inhibit peroxidasin (15). Cells were lysed and ECM was isolated as 
described above. Decellularised ECM was resuspended in PBS with sonication. The 
cross-linking reaction was initiated by adding Br¯ and H2O2, reagent HOBr or 
taurine bromamine (concentrations 50-100 μM, unless stated otherwise) to the 
isolated ECM (Figure 21). Other substrates and inhibitors were added at the 
concentrations stated in each figure. The standard incubation time was 60 minutes 
at 37°C unless stated otherwise. The reaction was stopped by adding a peroxidase 
inhibitor (sodium azide), or an appropriate oxidant scavenger (catalase or 
methionine), then the ECM was spun down and the supernatant was discarded. ECM 
was washed again to remove any residual oxidants before analysis. 





Figure 21. Schematic diagram for isolation of ECM and NCD from two systems, 
decellularised ECM or cell culture. 




Preparation of oxidants 
 Hydrogen peroxide (H2O2)  
A stock solution (30 %) was diluted 1:1000 in deionised H2O while vortexing. 
Concentration was determined by measuring its absorbance at 240 nm, (Extinction 
coefficient 43.6 M-1 cm-1). The concentration was calculated using Beer-Lambert 
Law: c= A/εl (c= concentration, A= absorbance, ε= extinction coefficient, l= length 
of the light path in cm). 
 Hypochlorous acid (HOCl) 
A stock solution of commercial chlorine bleach (Janola) was diluted 1:20 in PBS with 
vortexing. To determine the concentration, the working solution was diluted 1:10 
in 200 mM potassium hydroxide. The absorbance was measured at 292 nm 
(extinction coefficient 350 M-1 cm-1). Subsequent dilutions from this stock were 
made in PBS and kept on ice in the dark. 
 Hypobromous acid (HOBr) 
Fresh HOBr was prepared by mixing equal volumes of freshly prepared 19 mM HOCl 
and 20 mM potassium bromide and incubating in the dark for 15 minutes at room 
temperature. To determine the concentration, the solution was diluted 1:10 in 200 
mM potassium hydroxide. The absorbance was measured at 329 nm (extinction 
coefficient 335 M-1 cm-1). Subsequent dilutions from this stock were made in PBS 
and used for experiments within 30 minutes. 
 Taurine bromamine 
HOBr was gradually added to ten-fold excess of taurine. The mixture was kept on 
ice and used within 30 minutes.  
  




2.2.6 Determination of protein concentration 
Direct Detect® Infrared Spectrometer was used to measure protein concentration. 
The Direct Detect method uses Mid-Infrared (MIR) spectroscopy, which is based on 
the absorption of radiation in the range 4000-400 cm-1. Biomolecules 
(Carbohydrates, lipids, proteins, etc.) have distinct IR spectra and can be analysed 
concurrently. Measuring proteins utilises the distinct vibration of amides in the 
infrared region to calculate protein concentration. It requires spotting 2 µl of the 
sample or blank on a hydrophilic polytetrafluoroethylene (PTFE) membrane Assay 
Free® card and leaving it to dry then performing the reading with the Direct 
Detect® instrument.  
2.2.7 Gel electrophoresis 
Discontinuous mini gels were used to separate proteins by SDS-PAGE (190). For the 
analysis of dimer formation in the non-collagenous domain of collagen IV, 10-well 
12 % acrylamide gels were prepared (Table 9). For analysis of other samples, BIO-
RAD Mini-PROTEAN® TGX™ precast gels (4-15 %) were used. Protein loading was 
~ 5 µg of NCD samples for dimer analysis, and 25 µg of lysate for western blot 
analysis. 
Samples were mixed 5:1 with 5 x non-reducing sample buffer (Table 7). Samples 
were heated at 95°C for 3 minutes, spun down then loaded into the wells of the gel. 
Gels were run in Running Buffers (Table 7) at constant current (200 V) until the 
dye front ran off the gel (45-50 minutes). 
  




Table 9. Compositions of acrylamide gels. 
Gel type Stock solution Volume 
4 % stacking 0.5 M Tris pH 6.8 1.25 
 40 % (w/v) acrylamide 0.5 ml 
 dH2O  3 ml 
 20 w (w/v) SDS 25 µl  
 10 % (w/v) APS 25 ul 
 TEMED 8 µl 
12 % resolving 2 M Tris pH 8 2 ml 
 40 % (w/v) acrylamide 3 ml 
 dH2O  4.9 ml 
 20 % (w/v) SDS 50 µl  
 10 % (w/v) APS 50 ul 
 TEMED 15 µl 
   
2.2.8 Coomassie staining 
Commassie Brilliant Blue R-250 is a dye that interacts noncovalently with amino 
acids and is used to visualise protein bands on the gel (191). Gels were incubated in 
Coomassie R250 staining solution (Table 7) for 1 hour with shaking, then destained 
in multiple washes with Destain solution (Table 7) for 2 hours, then soaked in 
deionised H2O for a minimum of one hour.  
2.2.9 Densitometry analysis 
Gel imaging was performed using Alliance Uvitec Cambridge imager. Densitometry 
analysis was performed using Alliance software Uviband-max.  
 
2.2.10 Western blotting 
Proteins separated by SDS-PAGE were blotted on a polyvinylidene fluoride (PVDF) 
membrane by wet transfer (192). The PVDF membrane was activated by methanol, 
then equilibrated with the Transfer Buffer (Table 7). The polyacrylamide gel and 
PVDF membrane were assembled into a sandwich with filter paper and pads on 
each side then inserted into a BIO-RAD® tank with the Transfer Buffer. An icepack 
and a magnetic stirrer were also added to the tank. Proteins were transferred from 
the gel to the membrane at 100 V in 60 minutes. For larger proteins (e.g. 
peroxidasin), transfer took 18 hours at 33 mA at 4°C. After the transfer, the 




membrane was blocked with 5 % (w/v) non-fat milk or 3 % (w/v) BSA in TBST for 
one hour at room temperature on a rocker. The membrane was then incubated with 
the primary antibody in TBST for 18 hours at 4°C on a rocker (Table 10). The 
membrane was washed three times in TBST, 10 minutes each on a rocker. The 
secondary antibody was added in TBST with 5 % (w/v) milk or 3 % (w/v) BSA for 
one hour at room temperature on a rocker. Washing steps were repeated and the 
blot was developed using chemiluminescence and analysed by UVITEC Cambridge 
Gel imager.  
Table 10. Primary and secondary antibodies and dilutions. 
Primary antibody Dilution  Secondary antibody Dilution  
Rabbit polyclonal anti-peroxidasin 1:500 Goat anti-rabbit HRP 1:20,000 
Rabbit polyclonal anti-catalase 1:2000 Goat anti-rabbit HRP 1:20,000 
 
  




2.2.11 Proteomic identification of Peroxidasin  
To confirm the presence of peroxidasin in extracts from cells used as a model to 
study peroxidasin, a proteomic mass spectrometry method was developed by Dr. 
Louise Paton. The protocol for tryptic digestion of samples was followed as 
described in (193). Protein samples from intracellular lysate or ECM (400 μg) were 
dried in a SpeedVac then reconstituted in 50 μl of 100 mM ammonium bicarbonate 
buffer with vortexing. Samples were then mixed with 50 μl of the gel-aided sample 
preparation (GASP) buffer (40 % (w/v) acrylamide, 5 μl TEMED and 5 μl 10 % (w/v) 
APS) and allowed to polymerise for 10 minutes. The polymerised gel was then sliced 
into 1⨯1 mm pieces and fixed with 500 μl Fix solution (50 % methanol, 40 % HAc, 
10 % dH2O) for ten minutes with vortexing. The Fix solution was removed then 
samples were incubated with 500 μl acetonitrile for 10 minutes, spun down and the 
supernatant was discarded. Samples were submerged in reducing buffer (10 mM 
DTT in 100 mM ammonium bicarbonate) for 30 minutes at 56°C and washed again 
with 500 μl acetonitrile. Samples were submerged with alkylation buffer (55 mM 
iodoacetamide in 100 mM ammonium bicarbonate) for 20 minutes in the dark and 
washed again with 500 μl acetonitrile. Samples were submerged in protease buffer 
(10 mM ammonium bicarbonate, 10 % acetonitrile, protease 20 μg in 1.5 ml) and 
incubated at 4°C for 2 hours and topped up with protease buffer if necessary. 
Samples were left to digest at 37°C overnight. To extract peptides, 2 volumes of 
extraction buffer relative to digest were added to sample and incubated for 15 
minutes at 37°C with shaking. Supernatant was transferred to speed-vacuum 
Eppendorf tubes and dried in the SpeedVac. Peptides were reconstituted in 20 μl of 
0.1 % (v/v) formic acid, vortexed, and centrifuged for analysis by HPLC/MS. 
Semi-quantitative data was acquired with a QTRAP 6500 (SCIEX, Framingham, MA) 
coupled to an HPLC model 1290 (Agilent, Santa Clara, CA). Instrument control, data 
acquisition, and analysis were performed using Analyst 1.6.3 and PeakView 2.2. 
Samples were kept at 4°C in the autosampler prior to injection. Chromatographic 
separation was achieved on a Phenomenex Jupiter Proteo 90Å C12 (2.0 mm × 150 
mm, 4 μm) column with the column temperature set to 40°C. The mobile phase 
consisted of: solvent A, 0.1 % formic acid in water, and solvent B, 0.1 % formic acid 




in acetonitrile. The mobile phases were eluted at 250 uL/min. The gradient was as 
follows: 2 % B for 5 min, increased to 30 % B over 20 min, increased further to 98 
% B at 26 min, held for 5 min and then decreased to 2 % B at 32 min, followed by 5 
min equilibration. The QTRAP 6500 mass spectrometer was operated with the 
following parameters: Spray voltage: 5500 V, Temperature: 400 °C, Ion source gas 
1: 35, Ion source gas 2: 35, Declustering potential: 90, Entrance potential: 10, 
Collision cell exit potential: 14. The eluted peptides were analysed using multiple 
reaction monitoring. The doubly charged Y3 fragment of 675AGEIFER681 was 
monitored as a 411.4/451.3 transition (CE:23) and the Y5 fragment of 
1101AFFSPFR1107 was monitored as a 436.2/653.3 transition (CE:24). The area 
under the curve was used for quantitation. 
 
2.2.12 Peroxidase activity assay 
Amplex Red undergoes peroxidase-catalysed oxidation by H2O2 in a 1:1 
stoichiometry to produce resorufin, a red fluorescent compound (Figure 22). To 
measure peroxidase activity, 50 µM of Amplex red was added to the isolated ECM 
(~200-250 µg per sample resuspended and sonicated in 120 µl PBS) with 50 µM 
H2O2, incubated in the dark for 0-20 minutes and stopped by adding 1 mM azide. 
The ECM was spun down and 100 µl of supernatant was transferred to a 96-well 
plate to measure resorufin fluorescence (ex 544 nm, em 590 nm). 
 
Figure 22. Reaction scheme of Amplex red with hydrogen peroxide and peroxidase 
to produce fluorescent resorufin. 
  




2.2.13 Consumption of hydrogen peroxide in the isolated ECM 
The consumption of H2O2 in the isolated ECM was measured by the 
spectrophotometric FOX assay (ferrous ion oxidation of xylenol orange) (194). 
Hydrogen peroxide oxidises ferrous to ferric ion selectively (Eq. 1). The ferric 
sensitive dye xylenol orange (XO) binds to ferric ions to produce a blue-purple 
complex (Eq. 2), which is an indirect way to measure the concentration of hydrogen 
peroxide. 
Fe2+ + H2O2  Fe3+ + RO + OH⁻  Equation 1 
Fe3+ + XO  colored complex  Equation 2 
 
To make the FOX reagent, 25 mM sulfuric acid was added to 100 μM xylenol orange, 
250 μM ferrous ammonium sulfate and 100 mM sorbitol. It is essential to add the 
acid first before adding dH2O. The solution was used within 1 day of preparation. 
The isolated ECM (150-200 µg total protein in 120 µl final volume) was treated with 
50 µM H2O2 ± 100 µM Br¯, 50 µM PHG or 1 mM sodium azide. After various 
incubation times (2-60 min), the ECM was spun down, and 50 µl of the supernatant 
was mixed with 950 µl of FOX reagent with vortexing. Absorbance was measured 
after at least 40 minutes at 560 nm and related to a H2O2 standard curve (Figure 
23). 
  
Figure 23. Standard calibration curve for the concentration of H2O2. 
 




2.2.14 Measuring NADH bromohydrin by LC/MS  
Hypobromous acid reacts rapidly with NADH, adding across a C=C bond to form a 
bromohydrin (Apparent rate constant 4⨯106 M-1 s-1) (102) (Figure 24). This product 
was used to measure the production of HOBr by peroxidasin in the ECM. 
Decellularised ECM (~200 µg of ECM proteins) was incubated with 200 µM NADH, 
various concentrations of Br¯ and 50 or 100 µM H2O2 in 50 µl final volume of PBS 
for 2-25 minutes. The supernatant was separated and analysed for NADH and its 
bromohydrin products by LC-MS. A standard curve was generated by reacting 200 
µM NADH with reagent HOBr (5-500 nM) (shown later in Chapter 3). Samples were 
separated on a PS C18 (150x2.1 mm, Phenomenex, Framingham, USA) using a 
gradient of methanol (2-50 % over 10 min) in 10 mM ammonium acetate (pH 6.9) 
with a flow rate of 250 μl/min using an Ultimate 3000 pump (Thermo, San Jose, 
USA). The samples were delivered into a Velos Pro Ion Trap mass spectrometer 
(Thermo). Samples were detected using the selected reaction monitoring in the 
negative ion mode. The ion spray was set to -3.5kV and the interface heater to 300 
OC and the capillary was 275 OC. NADH was measured using the transition m/z 
664.2 to 408.1, and the bromohydrins by m/z 760.2 and 762.2 both going to m/z 
680.2. The collision gas was nitrogen and the collision energy was 30 % in each of 
the cases. Area of peaks were calculated using XCaliber Software (Thermo). Dr. 
Rufus Turner developed the LC/MS method.  
 
 
Figure 24. Reaction scheme for bromination of NADH by HOBr.  
  




2.2.15 Detection of hypobromous acid using the probe R19-S 
The fluorescent probe R19-S reacts with hypochlorous and hypobromous acids to 
produce the fluorescent product R19 (Figure 25) (195, 196). 
A 1 mM stock solution was prepared fresh weekly by dissolving R19S in acetonitrile 
and heating it at 50°C in the dark for 1 hour. To determine the concentration, the 
stock was diluted 1:200 in acetonitrile and its absorbance was measured at 308 nm 
(extinction coefficient 14100 M-1 cm-1) (195). Subsequent dilutions were made in 
sodium phosphate buffer. 
To detect the production of HOBr, decellularised ECM was homogenised by 
sonication in PBS and then incubated with 100 µM bromide, 50 µM hydrogen 
peroxide and 50 µM R19S probe and incubated for 60 minutes at 37°C. The reaction 
supernatant was removed and fluorescence was measured (ex 515 nm, em 550 nm). 
As a positive control, 5 µM reagent HOBr was added to the probe alone, or to the 
ECM and the probe.  
 
Figure 25. Reaction scheme of the probe R19-S with hypohalous acidsto yield a 
fluorescent probe R19. 
 
 




2.2.16 Measuring methionine sulfoxide 
A stable isotope dilution LC/MS/MS method was used for the detection and 
quantification of methionine and methionine sulfoxide. Isotopically-labelled 
standards (13C5 15N methionine and 13C5 15N methionine sulfoxide) were used to 
control for experimental variations, such as recovery, matrix effect and ionisation. 
The elution times of isotopically-labelled internal standards are the same as the 
unlabelled counterparts, but they differ in masses (Figure 26). 
To make isotopically-labelled methionine sulfoxide internal standards, 13C515N 
methionine was treated with a large excess of hydrogen peroxide (900 µl of 110 mM 
H2O2 to 100 µl of 10 mM methionine) and incubated at room temperature for 2 
hours. To remove excess H2O2 after the reaction, 0.25 µg/ml catalase was added to 
the mixture and incubated until air bubbles stopped forming. The FOX assay was 
used to test for any remaining H2O2. Reactants were analysed by LC-MS to ensure 
complete oxidation of methionine to methionine sulfoxide (Figure 27). 
To measure methionine sulfoxide in proteins, intracellular lysate or ECM samples 
were first digested to individual amino acids by pronase. Samples (50 µg) were 
placed in speed-vacuum Eppendorf tubes with internal standards (100 pmol 13C5 
15N Met and Met-O) and dried in a vacuum concentrator (SpeedVac). Pronase was 
added to protein samples in 1:10 ratio (w/w protein) in digestion buffer (5 µg 
pronase, 100 mM Tris buffer pH 7.5, 10mM CaCl2, 0.1 % (w/v) SDS). Samples were 
digested for 48 hours at 37°C. After digestion, samples were dried down in the 
SpeedVac and reconstituted in 22 µl of 10 mM ammonium formate pH 3.8 for 
analysis by LC-MS. 
Samples were separated on a Hypercarb™ Porous Graphitic Carbon column 
(250x2.1 mm) using an Agilent 1290 Binary Pump at a flow rate of 200 µl/ minute. 
The mobile phase gradient started with 100 % 10 mM ammonium formate that 
gradually decreased over seven minutes to 65 % and 35 % acetonitrile. The column 
was washed with 100 % organic solvent for five minutes then equilibrated with the 
starting eluent (Table 11). The analytes were delivered into a Qtrap® 6500 mass 




spectrometer (Sciex) and detected in multiple reaction monitoring mode using the 
positive ionisation mode. The ion spray was set to -3.5kV and the interface heater 
to 300 OC and the capillary was 275 OC. The collision gas was nitrogen and the 
collision energy was 30 %. Area of peaks were calculated using XCaliber Software 
(Thermo). Mass spectra and fragmentation patterns for methionine and methionine 
sulfoxide are shown in Figure 28, Figure 29 and Table 12. Standard calibration 
curves for methionine and methionine sulfoxide are shown in Figure 30. 
  





Figure 26. Typical LC/MS/MS chromatograms for the analysis of Met, isotopically-
labelled 13C515N methionine, methionine sulfoxide and isotopically-labelled 13C515N 
methionine sulfoxide. Structures of methionine and methionine sulfoxide with their 
isotopically-labelled atoms (*) are shown in the insets. 
  





Figure 27. Generation of labelled Met-O. The loss of 13C515N Met () and formation of 
13C515N Met-O () are monitored by LC/MS/MS analysis over time of incubation with H2O2.  
 
Table 11. Composition of the mobile phase for elution of Met and Met-O. Buffers: A: 10 
mM ammonium formate, pH 3.8 (made fresh weekly. pH adjusted with formic acid), B: 
Acetonitrile.  
Time (min)  % A  % B 
0 100 0 
7 65 35 
7.1 0 100 
12 0 100 
12.1 100 0 
17 100 0 
   
 
  




Table 12. Analysis of Met and Met-O by MS. Analytes, mass-to-charge ratios and 
fragments monitored in the multiple reaction monitoring positive ionisation mode. Q, 
transition used for quantitation; C, transition used for the confirmation of the presence of 
the analyte. 





Met 150 61 C 
150 56 C 
150 104 Q 
150 133 C 
Met-O 166 102 C 
166 149 C 
166 74 Q 
166 56 C 
13C5 15N Met 156 138 C 
156 109 Q 
156 63 C 
156 107 C 
13C5 15N Met-O 172 77 Q 
172 107 C 
172 125 C 
172 154 C 
 
  









Figure 28. The mass spectra and fragmentation patterns of Met. (a) Methionine (m/z 
150) and (b) isotopically-labelled 13C515N methionine (m/z 156). In addition to parent ions 
(MH]+, fragments and functional groups lost are shown. Structure of methionine and 
labelled heavy isotope atoms (*) are shown in the insets. 
 
  








Figure 29. The mass spectra and fragmentation patterns of Met-O. (a) methionine 
sulfoxide (m/z 166) and (b) isotopically-labelled 13C515N methionine sulfoxide (m/z 172). 
In addition to parent ions [MH]+, fragments and functional groups lost are shown. Structure 
of methionine sulfoxide and labelled heavy isotope atoms (*) are shown in the insets. 
  








Figure 30. Standard calibration curves for (a) Met and (b) Met-O Range 0.1-300 pmol. 
Insets show signal-to-noise ratios for 100 fmol.  




2.2.17 Measuring 3-bromotyrosine  
A stable isotope dilution LC/MS/MS method was used for the detection and 
quantification of 3-bromotyrosine levels in proteins (89, 197). Isotopically-labelled 
standards (13C6 tyrosine and 13C9 3-bromotyrosine) were used to control for 
experimental variations, such as recovery, matrix effect and ionisation. The elution 
times of isotopically-labelled internal standards are the same as the unlabelled 
counterparts, but they differ in mass (Figure 31 and Table 13). Artefactual 
bromination was monitored by measuring any conversion of 13C6 tyrosine to 13C6 3-
bromotyrosine. 
Protein samples were first hydrolysed to individual amino acids. Intracellular 
lysate, ECM and NCD (50 µg) were placed in Kimble tubes with internal standards 
(6 nmol 13C6 Tyr and 6 pmol 13C9 3-Br-Tyr) and dried in the SpeedVac. Then, 100 µl 
of 4 M methane sulfonic acid, supplemented with 1 % (w/v) phenol, was added to 
each tube and vortexed. The Kimble tubes were then placed into a capped vial, 
flushed with nitrogen four times and sealed under positive pressure. The vial was 
then placed in an oven inside a fume cupboard, and left at 110°C for 18 hours.  
After hydrolysis, samples were left to cool down at room temperature before 
opening the vial. Kimble tubes were removed from the vial, and their content was 
diluted with 500 µl dH2O with 0.1 % (v/v) trifluoroacetic acid (TFA) and vortexed. 
The hydrolysate was processed by solid phase extraction (SPE) to remove the acid. 
C-18 cartridges were first conditioned with 3 ml methanol, followed by 2 ml dH2O 
with 0.1 % (v/v) TFA, without allowing cartridges to dry. Samples were then loaded 
onto cartridges, washed with 2 ml dH2O with 0.1 % (v/v) TFA. To elute the analytes, 
1.1 ml 80 % (v/v) methanol was added to cartridges and collected in speed-vacuum 
Eppendorf tubes. Samples were dried in the SpeedVac and reconstituted in 22 µl 
dH2O with 0.1 % (v/v) formic acid for analysis by HPLC-MS/MS. 
Samples were separated on a Kinetex® 2.6 µm C18 100Å column (150x2.1 mm), 
using an Agilent 1290 Binary Pump at a flow rate of 200 µl/ minute in a mobile 
phase outlined in Table 14. The gradient started with 2 % organic solvent 




(acetonitrile with 0.1 % (v/v) formic acid) for four minutes, followed by a gradual 
increase of organic solvent concentration to 80 % for three minutes. The column 
was washed with 80 % organic solvent for three minutes then equilibrated with the 
starting eluent.  
The analytes were delivered into a Qtrap® 6500 mass spectrometer (Sciex) and 
detected in multiple reaction monitoring mode using positive ion mode. The ion 
spray was set to -3.5kV and the interface heater to 300 OC and the capillary was 
275OC. The collision gas was nitrogen and the collision energy was 30 %. The areas 
of peaks were calculated using XCaliber Software (Thermo). Examples of mass 
spectra and fragmentation patterns for tyrosine and 3-bromotyrosine are shown in 
Figure 32. Standard calibration curves for tyrosine and 3-bromotyrosine are 
shown in Figure 33. 
  





Figure 31. Typical LC/MS/MS chromatograms for analysis of Tyr, isotopically-
labelled 13C6 Tyr, 3-Br-Tyr and isotopically-labelled 13C9 3-Br-Tyr. Structures of 
tyrosine and 3-bromotyrosine with their isotopically-labelled atoms (*) are shown in the 
insets. 
  




Table 13. Analysis of Tyr and 3-Br-Tyr by MS. Analytes, mass-to-charge ratios and 
fragments monitored in the multiple reaction monitoring positive ionisation mode. 
Analyte  Precursor ion (m/z) Product ions (m/z) 
12C Tyr Sample 182 136, 165 
13C6 Tyr Internal standard 188 171 
12C 3-Br79-Tyr Sample 260 214 
12C 3-Br81-Tyr Sample 262 216 
13C6 3-Br79-Tyr Artefact bromination 266 220 
13C6 3-Br81-Tyr Artefact bromination 268 222 
13C9 3-Br79-Tyr Internal standard 269 222 
13C9 3-Br81-Tyr Internal standard 271 224 
 
Table 14. Composition of the mobile phase for elution of Tyr and 3-Br-Tyr. Buffers A: 
dH2O with 0.1 % (v/v) formic acid, and B: acetonitrile with 0.1 % (v/v) formic acid. 
Time (min)  % A  % B 
0 98 2 
4 98 2 
7.1 20 80 
10 20 80 
10.1 98 2 
15 98 2 
  




a          
 
b          
 
Figure 32. The mass spectra and fragmentation patterns of Tyr and 3-Br-Tyr. (a) 
Tyrosine (m/z 181) and (b) 3-bromotyrosine (m/z 260).In addition to parent ions [MH]+, 
fragments and functional groups lost are shown. Structures of tyrosine and 3-
bromotyrosine are shown in the insets.   








Figure 33. Standard calibration curves for Tyr and 3-Br-Tyr. (a) tyrosine in a range of 
0.1-10 nmol and (b) 3-bromotyrosine in a range of 0.1-10 pmol. Insets show signal-to-noise 
ratios for 100 pmol for tyrosine and 100 fmol for 3-bromotyrosine. 
  




2.2.18 Measuring 3-nitrotyrosine 
The method development for measurement of 3-nitrotyrosine is described in 
Chapter 5. Here I describe the final version of the optimised method. A stable 
isotope dilution LC/MS/MS method was used for the detection and quantification 
of 3-nitrotyrosine levels in proteins (198). Isotopically-labelled standards (13C6 
tyrosine and 13C9 3-nitrotyrosine) were used. Chromatograms of 3-nitrotyrosine 
and 13C9 3-nitrotyrosine are shown in Figure 34. Information on tyrosine standards 
are described earlier in Section 2.2.17. 
ECM samples were first hydrolysed to individual amino acids. Samples (50 µg) were 
placed in Kimble tubes with internal standards (6 nmol 13C6 Tyr and 6 pmol 13C9 3-
NO2-Tyr) and dried in the SpeedVac. Then 100 µl of 6 M hydrochloric acid (HCl), 
supplemented with 1 % (w/v) phenol, was added to each tube and vortexed. The 
Kimble tubes were then placed into a capped vial, flushed with nitrogen gas four 
times and sealed under positive pressure. The vial was then placed in an oven inside 
a fume cupboard, and left at 110°C for 18 hours.  
After hydrolysis, samples are left to cool down at room temperature before opening 
the vial. The Kimble tubes were removed from the vial, and the content was diluted 
by adding 500 µl dH2O with 0.1 % (v/v) TFA and vortexed. The hydrolysate was 
processed by SPE to remove the acid. Cartridges (Strata® C18-E (55 µm, 70 Å), 200 
mg / 3 mL) were first conditioned with 5 ml methanol, followed by 2 ml dH2O with 
0.1 % (v/v) TFA, without allowing cartridges to dry. Samples were then loaded onto 
cartridges, washed twice with 2 ml dH2O with 0.1 % (v/v) TFA. The analytes were 
eluted in 1.1 ml 30 % (v/v) methanol in 0.1 % (v/v) TFA, dried in the SpeedVac and 
reconstituted in 22 µl dH2O with 0.1 % (v/v) formic acid for analysis by HPLC-
MS/MS. 
The HPLC method, mobile phase, column and other settings are the same as 
described earlier in Section 2.2.17. The masses and transitions monitored for 3-
nitrotyrosine are listed in Table 15 and Figure 35. Standard calibration curves for 
3-nitrotyrosine is shown in Figure 36. 





Figure 34. Typical LC/MS/MS chromatograms for analysis of 3-NO2-Tyr and 
isotopically-labelled 13C9 3-NO2-Tyr. Structures of 3-nitrotyrosine and its isotopically-
labelled atoms (*) are shown in the insets. 
 
Table 15. Analysis of 3-NO2-Tyr by MS. Analytes and ions monitored for analysis of 3-
NO2-Tyr and isotopically-labelled 3-NO2-Tyr.  
Analyte Precursor ion (m/z) Product ions (m/z) 
12C NO2-Tyr 227 181, 210 
13C6 NO2-Tyr 233 187, 216 
13C9 NO2-Tyr 236 189, 219 
 
 





Figure 35. The mass spectrum and fragmentation pattern of 3-NO2-Tyr. In addition to 
parent ions (MH]+ (m/z 227), fragments and functional groups lost are shown. Structure 3-
nitrotyrosine is shown in inset. 
 
 
Figure 36. Standard calibration curve for 3-NO2-Tyr. Range 0.1-5 pmol. Inset shows 
signal-to-noise ratios for 100 fmol 3-nitrotyrosine. 
 
  




2.2.19 Statistical analysis 
Data are presented as means and standard errors of the mean, unless stated 
otherwise. Independent repeats stated in figure legends refer to biological repeats. 
Any technical repeats are averaged and counted as one biological repeat. Statistical 
significance was performed on data sets derived from three or more independent 
biological repeats and calculated by multiple comparison analysis of variance 
(ANOVA) or paired t-tests. A level of significance was set at p<0.05. The software 
Prism GraphPad was used for data analysis. 
 
Chapter 3 Enzymology of Peroxidasin in the ECM 
 
The main findings in this chapter are published in: Bathish, B., et al., Characterisation of 
peroxidasin activity in isolated extracellular matrix and direct detection of hypobromous acid 
formation. Arch Biochem Biophys, 2018. 646: p. 120-127. (199) 
3.1. Background 
The physiological role of peroxidasin as the enzyme responsible for the sulfilimine 
cross link in collagen IV was revealed only recently (33). Peroxidasin catalyses the 
formation of the cross links between juxtaposed methionine and hydroxylysine at 
the non-collagenous domain (NCD) ends of collagen IV protomers. Peroxidasin 
oxidises bromide, and it is inferred that it produces HOBr, which is responsible for 
generating the cross link. The peculiar anabolic function of peroxidasin-produced 
HOBr poses a paradigm shift for the role of the otherwise destructive oxidant. The 
role of bromide in the collagen IV cross-linking reaction is the first essential 
function in mammals to be known of this trace element (35). The low physiological 
levels of bromide and the presence of other halides that are typical peroxidase 
substrates (140 mM Cl⁻, 20-100 µM Br⁻, 20-120 µM SCN⁻, 0.1-0.5 µM I⁻) raise 
questions about specificity and competition (14). Although there is compelling 
evidence that peroxidasin uses bromide to cross-link collagen IV, to date there has 
been no direct evidence that peroxidasin produces HOBr in the ECM. It is also not 
known whether peroxidasin releases HOBr into its surroundings or undergoes a 
concerted reaction with collagen IV in the ECM. In this chapter I explore some of the 
questions regarding peroxidasin substrate requirement, specificity and inhibition.  
Peroxidasin is a highly-glycosylated homotrimer with multiple domains that are 
essential for protein-protein interactions in extracellular proteins. The intrinsic 
properties of peroxidasin make it difficult to purify or recombinantly express the 
protein for enzymatic studies. These technical difficulties prevent access to a pure 




enzymatic system to probe the enzymology of a native full-length active form of 
peroxidasin.  
As an alternative model system to the pure enzyme, the activity of peroxidasin can 
be investigated in the ECM. The mouse epithelial cell line, PFHR9 has been used in 
many studies that have characterised collagen IV cross-linking (33, 35, 49). These 
cells secrete ECM that contains associated peroxidasin. When they are grown for 6-
8 days, an appreciable amount of ECM can be isolated after lysing the cells and then 
subsequently used to investigate the activity of peroxidasin within the matrix. 
When the cells are cultured in the presence of phloroglucinol (PHG), a reversible 
peroxidasin inhibitor (15), the secreted collagen IV is not cross-linked (33). Isolated 
uncross-linked ECM can then be treated with H2O2 and various peroxidase 
substrates and inhibitors, to investigate the modulation of peroxidasin enzymatic 
activity in situ. The peroxidasin-knockout PFHR9 cell line has been used in this 
study as a negative control. Cross-linking was analysed by isolating the NCD of 
collagen IV and resolving it by SDS-PAGE. Monomers and dimers were identified by 
Coomassie Blue staining and quantified by densitometry quantification. 
 
  





3.2.1 Identification of peroxidasin 
To confirm the presence of peroxidasin in the epithelial cells to be used as the 
experimental model, lysate and ECM isolated from PFHR9 cells were analysed by 
mass spectrometry and immunoblotting. The mass spectrometry method was 
developed by Dr. Louise Paton. The full method is outlined in Chapter 2. Two unique 
tryptic peptides were identified in the peroxidase domain of peroxidasin 
(675AGEIFER681 and 1101AFFSPFR1107). The two peptides were used for identification 
of peroxidasin, and only the second peptide was used for semi-quantification in the 
intracellular extract and ECM of PFHR9 cells (Figure 37a). 
The peptide 1101AFFSPFR1107 was three-fold higher in the ECM than in the 
intracellular lysate. Neither of the peptides were detected in the peroxidasin-
knockout PFHR9 cells.  
For immunoblotting, lysate from PFHR9 cells and mouse epithelial fibroblast (MEF) 
cells were blotted and probed with anti peroxidasin antibody. In both cell lines, high 
molecular weight bands appeared to be consistent with being the 500 kDa trimeric 
peroxidasin (Figure 37b).  
The mass spectrometry and immunoblotting data provide sufficient evidence that 
peroxidasin is present in the cell model system. 
  





    
Figure 37. Detection of peroxidasin in the cell system. (a) The relative abundance of the 
peroxidasin tryptic peptide 1101AFFSPFR1107 in 400 µg protein of intracellular extract (black 
bar) and extracellular matrix (grey bar) analysed by mass spectrometry (n=2 biological 
repeats). N.D., nothing detected (b) Lysate from mouse embryonic fibroblast (MEF) cells, 
and mouse epithelial cells (PFHR9) blotted under non-reducing conditions and probed for 
peroxidasin with anti-peroxidasin antibody. 
  














3.2.2 Peroxidase activity in the isolated decellularised ECM 
The Amplex red assay was used to measure peroxidase activity in the isolated 
decellularised ECM to establish whether peroxidasin is in fact active in the ECM as 
a general peroxidase. Treatment of the isolated ECM with H2O2 resulted in the 
oxidation of Amplex red to fluorescent resorufin, and this activity was fully 
inhibited by PHG (peroxidasin inhibitor) and azide (general heme poison) (Figure 
38). No peroxidase activity was detected in ECM isolated from peroxidasin-
knockout cells. These results demonstrated that peroxidasin localised in the ECM 
was active, accessible and able to oxidise external substrates such as Amplex red. 
Notably, the fluorescence increase after 30 min with peroxidasin and 50 µM H2O2, 
corresponded to the response with less than 1 µM H2O2 when compared with H2O2 
standard curve (not shown). This implies that only a small fraction of the H2O2 
added to the ECM was consumed by peroxidase activity.   
 
Figure 38. Peroxidase activity in the isolated decellularised ECM. Isolated ECM grown 
in the presence of PHG (200-250 µg per sample in 120 µl final volume of PBS) was incubated 
with 50 µM Amplex red + 50 µM H2O2 only (), or + 50 µM PHG (🔺), + 1 mM azide (🔻), or 
50 µM H2O2 + ECM isolated from peroxidasin-knockout cells (). The reaction was 
quenched by adding 1 mM azide and ECM was spun and 100 µl of the supernatant was 
transferred to 96 well plate to measure fluorescence (ex 544 nm/em 590 nm). In a standard 
curve of Amplex red, H2O2 and horseradish peroxidase, 0.5 µM H2O2 gives fluorescent signal 
of ~60 units. Values represent mean of 3 independent experiments ± SEM. 
  




3.2.3 Detection of HOBr formation in the extracellular matrix 
The production of HOBr by peroxidasin was investigated by adding NADH to 
isolated decellularised ECM and analysing the reaction products. HOBr reacts 
rapidly with NADH (102), and adds across a double bond of the nicotinamide ring 
to produce bromohydrin isomers. Following NADH bromohydrin formation by 
mass spectrometry can provide definitive evidence for HOBr production, because 
bromine is incorporated into the products. Naturally occurring bromine occurs in 
equal proportions of two isotopes that differ by two mass units (79Br and 81Br), 
which give a distinctive MS pattern.  
To establish the assay, oxidation of NADH by reagent HOBr was monitored by a 
LC/MS assay. Unreacted NADH (m/z 664) ran as a peak at 3.5 min (Figure 39a). 
After treatment with HOBr, two new peaks appeared at 4.5 and 6 min with the 
expected mass and isotopic distribution for HOBr addition (m/z 760.2 and 762.2). 
These are likely to be different bromohydrin isomers, depending on the form of 
addition across the double bond. The area of the major bromohydrin peak showed 
a linear response to low concentrations of HOBr (Figure 39b). When isolated 
decellularised ECM was incubated with NADH, Br¯ and H2O2, progressive 
bromohydrin formation over time was detected (Figure 40a). This increased with 
increasing bromide concentration up to 200 µM (Figure 40b). There was no 
difference between bromohydrin formation with 50 or 100 µM H2O2. As expected 
for a peroxidasin-dependent reaction, no bromohydrin formation was detected 
when the ECM was treated with PHG, or in ECM isolated from peroxidasin-knockout 
cells. Relating the ratio of bromohydrin to NADH peak areas measured with the ECM 
system to the HOBr standard curve (Figure 39b) gives a maximum of ~500 nM 
HOBr trapped by the NADH (Figure 40b). Thus HOBr was produced but the amount 
trapped corresponded to ~1% of the H2O2 added. 
  






Figure 39. Reaction of HOBr with NADH to form NADH bromohydrin. (a) 
Chromatogram obtained in selective reaction mode for NADH (m/z 664.2 to 408.1, solid 
line) and the two bromine isotopes of bromohydrin (bromohydrin 1, m/z 760.2 to 680.2 in 
dashed line, bromohydrin 2, m/z 762.2 to 680.2, overlaid dotted line). (b) Standard curve 
of reacting NADH (200 µM) with reagent HOBr. Ratios were calculated from the 
bromohydrin peak areas and represent a combination of both isotopes. Values represent 










Figure 40. Oxidation of NADH to bromohydrin by decellularised ECM. (a) Ratio of 
bromohydrin to NADH peak areas when ~200 μg of isolated ECM from cells grown in the 
presence of PHG was incubated with 200 µM NADH, 50 µM H2O2 and 100 µM Br¯ at 37°C, 
and the reaction was quenched by adding 1 mM azide after the indicated times. (b) Ratio of 
bromohydrin to NADH peak areas after adding increasing concentrations of Br¯ plus 50 µM 
() or 100 µM H2O2 () to ECM and 200 µM NADH; or 100 µM Br¯ + 50 µM H2O2 with 50 
µM PHG (), or with ECM from peroxidasin-knockout cells () for 15 min. Values 









The fluorescent probe R19-S reacts with hypochlorous and hypobromous acids to 
produce the fluorescent product R19 (195, 196). This probe was tested to 
determine whether it could be used to detect HOBr formation in isolated 
decellularised ECM. When the probe was mixed with reagent HOBr, it formed the 
fluorescent product (Figure 41a). As previously reported, the yield was lower with 
HOBr than with HOCl (196). When the probe was added to the isolated ECM with 
Br⁻ and H2O2, no fluorescence was detected (data not shown). It is possible that the 
amount of HOBr produced in the ECM is very low and it reacts faster and more 
selectively with the ECM components than with the R19 probe. To test this 
hypothesis, reagent HOBr was mixed with the R19 probe in presence or absence of 
isolated ECM. In the presence of ECM, the fluorescence signal produced was 
negligible when compared to the signal produced when mixing the same amount of 
reagent HOBr with the R19 probe only (Figure 41b). Even when the R19-S probe 
was pre-incubated with reagent HOBr, the signal was reduced to a third after mixing 
with the ECM. Therefore, the probe was proven not suitable for this system.  
In conclusion, the detection of peroxidasin-dependent oxidation of NADH to 
bromohydrin is evidence that HOBr is being released as a product of peroxidasin 
activity in the isolated decellularised ECM. 
  






Figure 41. Reaction of HOCl and HOBr with the probe R19-S. (a) Titration of HOBr () 
or HOCl () with 50 µM R19-S probe and measuring fluorescence (ex 515 nm, em 550 nm). 
(b) Fluorescence signal when 5 µM HOBr was mixed with 50 µM R19-S probe only (bar 1), 
when HOBr was pre-incubated with the R19-S probe for 2 minutes before adding to ECM 










3.2.4 Substrate requirement for collagen IV cross-linking 
Under normal cell culture conditions in growth medium, the non-collagenous 
domain (NCD) of collagen IV isolated from PFHR9 cells is ~70% cross-linked via 
one or two sulfilimine bonds to give dimers (designated D1 and D2) with different 
electrophoretic mobilities (Figure 42a and b, lane 1). When PHG, a reversible 
inhibitor of peroxidasin, was added to the cell culture medium, the proportion of 
dimer in the subsequently isolated ECM was decreased to ~15% (Figure 42a and 
b, lane 2). When the isolated decellularised uncross-linked ECM was treated with 
H2O2 and Br¯, the monomers were cross-linked (Figure 42a and b, lane 3). Collagen 
IV isolated from peroxidasin-knockout cells was not cross-linked (Figure 42a and 
b, lane 4). This uncross-linked ECM was used as a model system to investigate the 
cross-linking reaction by the embedded peroxidasin. When the uncross-linked ECM 
was treated with Br¯ and H2O2, the NCD cross link was progressively formed to a 
maximum of ~55% after 30-60 min (Figure 43). Cross-linking required both Br¯ 
and H2O2. It was near maximal with ~10 µM H2O2 regardless of the Br¯ 
concentration (Figure 44) and increased with Br¯ concentration up to at least 200 
µM (Figure 45).   








Figure 42. Collagen IV cross-linking in cell culture or decellularised ECM. (a) 
Coomassie-stained gel showing monomers and dimers of collagen IV NCD isolated from 
PFHR9 cells grown in the absence (lane 1) and presence (lane 2) of 50 µM PHG during 
deposition of ECM, or when grown in PHG then ECM was isolated and treated with 50 µM 
H2O2 and 100 µM Br¯ for 1 hour (lane 3). The left lane shows molecular weight markers. In 
a separate gel, NCD from peroxidasin-knockout cells (KO) treated with 50 µM H2O2 and 100 
µM Br¯ for 30 minutes is shown. (b) Densitometry analysis of the gel bands. In all figures, 
the NCD (~5 μg per sample) was isolated by digestion with collagenase, purified, separated 
by SDS-PAGE and stained with Coomassie blue. Gel images are representative of ≥3 
independent experiments. Percentage dimer was calculated by dividing the densitometry 
signal of the two dimer bands by the total signal of dimers and monomers within each lane 
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Figure 43. Collagen IV cross-linking in decellularised ECM. (a) Coomassie-stained gel 
showing monomers and dimers of collagen IV NCD isolated from PFHR9 cells grown in the 
presence of 50 µM PHG during deposition of ECM, then ECM was isolated and treated with 
50 µM H2O2 and 100 µM Br¯ for 0-90 minutes at 37°C. The left lane shows molecular weight 
markers. (b) Densitometry analysis of the time course for dimer formation as detailed in 
(a). Percentage dimer was calculated as in Figure 42. Densitometry values represent mean 
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Figure 44. The effect of H2O2 concentrations on the cross-linking. (a) Commassie-
stained gel showing dimer formation after treating uncross-linked ECM for 1 hr at 37°C in 
PBS with 50 µM Br¯ and increasing concentrations of H2O2. (b) Densitometry analysis of 
H2O2 dependence with 50 µM () and 100 µM Br¯ (). Gel images are representative of ≥3 
independent experiments. Percentage dimer was calculated as in Figure 42. Densitometry 
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Figure 45. The effect of bromide concentration on the cross-linking. (a) Commassie-
stained gel showing dimer formation after treating uncross-linked ECM for 1 hr at 37°C in 
PBS with 50 µM H2O2 and increasing concentrations of Br¯. (b) Densitometry analysis of Br¯ 
dependence with 50 µM () and 100 µM H2O2 (). Gel images are representative of ≥3 
independent experiments. Percentage dimer was calculated as in Figure 42. Densitometry 























3.2.5 Consumption of hydrogen peroxide in the decellularised ECM  
Surprisingly high concentrations of H2O2 (~50 μM) were required for maximal 
dimer formation in the isolated decellularised ECM. Oxidation of Amplex red or 
NADH accounted for only a small fraction of the H2O2 added. To investigate the 
reason for this low stoichiometry, the consumption of H2O2 by the ECM was 
monitored using the ferrous oxidation-xylenol orange (FOX) assay. The majority of 
the H2O2 was consumed over 30 minutes irrespective of the absence or presence of 
bromide or PHG (Figure 46a). This time course mirrored the time courses for 
collagen IV cross-linking, Amplex red oxidation and NADH bromohydrin formation. 
Given that cross-linking only occurred when both H2O2 and Br¯ were added (Figure 
46b), it appears that most of the H2O2 was consumed independently of these 
reactions. The H2O2 consumption was not due to peroxidasin, as it was just as rapid 
with ECM isolated from peroxidasin-knockout cells. However, consumption was 
inhibited by azide, indicating the involvement of a heme enzyme. With no other 
substrate present, I suspected catalase activity. Indeed I saw consumption of H2O2 
in a standard catalase assay that measures loss of absorbance at 240 nm when ECM 
was added. The assay used 10 mM H2O2 and was accompanied by bubble formation 
as expected for O2 evolution due to catalase action. However, I did not detect the 
presence of catalase in the isolated ECM by immunoblotting for catalase (Figure 
46c). One possibility is that a small amount of intracellular catalase was released 
during cell lysis and bound to the ECM, although extra washing steps with high salt 
or urea did not decrease the activity. Regardless of the source of catalase activity, it 
clearly consumed most of the H2O2 added to the ECM, and this explains why the 
peroxidasin-dependent reactions occurred with apparently low efficiency. 
 




              
                             
                          
Figure 46: Consumption of H2O2 by the decellularised ECM. (a) ECM (~150-200 µg per 
sample in 120 µl final volume PBS) was incubated with 50 µM H2O2 alone (), or 50 µM 
H2O2 with 100 µM Br¯ (), 50 µM PHG (), 1 mM azide (), or 50 µM H2O2 + ECM isolated 
from peroxidasin-knockout cells (). The reaction was quenched with 1 mM azide (N3⁻) at 
each time point, and 50 µl of the supernatant was mixed with 950 µl FOX reagent. 
Absorbance was measured at 560 nm. Values represent mean of 3 independent 
experiments. For clarity, error bars are shown in one direction. (b) Gel showing dimers and 
monomer of NCD from collagen IV cross-linked in ECM isolated from cells grown in PHG, 
then treated as indicated with H2O2 and Br⁻, PHG, or azide. (c) Immunoblot analysis of 
catalase (MW 60 kDa) using anti catalase antibody. Different samples analysed for the 
presence of catalase: 25 ng of pure bovine catalase as a positive control (lane 1), total cell 
lysate from PFHR9 cells (lane 2), intracellular extract (lane 3), isolated ECM (lane 4), lysate 
from red blood cells as a positive control (lane 5). Immunoblot image is representative of 
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3.2.6 Cross-linking collagen IV with taurine bromamine and HOBr 
Previous evidence points to collagen IV cross-linking being due to HOBr generated 
by peroxidasin. Bromamines, which are produced by the reaction of HOBr with 
amine groups, retain the oxidising capability of HOBr (200) and contribute to 
sulfilimine formation in Met- and Lys-containing small peptides (172). Based on 
these findings, cross-linking efficiency was compared between taurine bromamine, 
reagent HOBr and the enzymatic system with Br¯ plus H2O2. The cross link was 
formed with reagent HOBr and taurine bromamine, although less efficiently than 
with the enzymatic system (Br¯ + H2O2 + native ECM-bound peroxidasin) especially 
in forming dimer 2 (Figure 47a, b). As expected (35), negligible cross-linking was 
promoted by hypochlorous acid (Figure 48a, b).  
  






Figure 47. Cross-linking collagen IV in decellularised ECM. (a) Commassie-stained gel 
showing dimer formation after treating uncross-linked ECM for 1 hr at 37°C in PBS with 
Br¯ + H2O2, reagent HOBr or taurine bromamine (TauBr) with the concentrations indicated 
below the gel in µM. (b) Densitometry analysis of dimer formation in conditions described 
in (a), 100 µM (black bars), 200 µM (grey bars) of the indicated substrates/reagents. Gel 
images are representative of ≥3 independent experiments. Percentage dimer was 
calculated as in Figure 42. Densitometry values represent mean of ≥3 independent 
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Figure 48. Cross-linking collagen IV by hypohalous acids. (a) Silver-stained gel 
showing dimer formation  after treating uncross-linked ECM for 1 hr at 37°C in PBS with 
reagent HOBr or HOCl. (b) Densitometry analysis of dimer formation in correspondence 
to increasing concentrations of HOBr () or HOCl (). Gel images are representative of 
≥3 independent experiments. Percentage dimer was calculated as in Figure 42. 
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3.2.7 Modulation of collagen IV cross-linking by endogenous substrates 
The halides chloride, bromide and iodide and the pseudohalide thiocyanate are 
physiological substrates (two electron donors) for heme peroxidases (201). The 
effects of these substrates on collagen IV cross-linking was tested in the isolated 
decellularised ECM. Chloride did not interfere with bromide, as all cross-linking 
reactions were carried out in 140 mM NaCl. Iodide and thiocyanate both inhibited 
dimer formation when added with Br¯ and H2O2 (Figure 49a, b). In each case, the 
concentration-dependence of inhibition was similar at 50 and 100 µM Br¯, with 200 
µM iodide inhibiting dimerisation by ~30%, and 200 µM thiocyanate by ~50% 
(calculated as a proportion of the difference between maximum dimerisation of 
70% and 10% dimers in the starting material). Thus iodide inhibited only at much 
higher than physiological concentrations, whereas inhibitory concentrations of 
thiocyanate were in the physiological range.  
Urate and ascorbate are substrates for peroxidasin (one-electron donors) (47), as 
well as good oxidant scavengers. Low concentrations of urate inhibited 
dimerisation to a maximum of ~35% with an IC50 of ~20 µM (Figure 50a). The 
extent of inhibition was similar at 50 and 100 µM bromide. Ascorbate had a minimal 
effect on cross-linking (Figure 50b). 
  







Figure 49. The effects of iodide and thiocyanate on the cross-linking. ECM isolated 
from epithelial cells grown with PHG was treated with (50 µM or 100 µM) Br¯ + 50 
µM H2O2 + the indicated concentrations of (a) iodide or (b) thiocyanate in PBS for 1 hour 
at 37°C. ECM digestion, purification of NCD and analysis of dimer as in Figure 42. 
Percentage dimer was calculated as in Figure 42. Densitometry values represent mean of 
≥3 independent experiments ± SEM. 
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Figure 50. The effects of urate and ascorbate on the cross-linking.  ECM isolated from 
epithelial cells grown with PHG was treated with (50 µM or 100 µM) Br¯ + 50 µM H2O2 
+ the indicated concentrations of (a)urate or (b) ascorbate in PBS for 1 hour at 37°C. ECM 
digestion, purification of NCD, analysis of dimer as in Figure 42. Densitometry values 
represent mean of ≥3 independent experiments ± SEM. Structures of uric acid and ascorbic 








The observed effects of the inhibitors could be due to them acting as competitive 
substrates for peroxidasin, as well as scavengers of HOBr being produced by 
peroxidasin. When comparing the effects on cross-linking with reagent HOBr versus 
the enzymatic system (Br + H2O2 + embedded peroxidasin), iodide, thiocyanate and 
urate all showed significant inhibition in the enzymatic system, indicating that they 
acted as substrates for peroxidasin (Figure 51). These scavengers had varied 
effects when added with reagent HOBr. Their inhibition of cross-linking is not 
statistically significant. However, a closer look at the effect of thiocyanate shows 
that it actually inhibited cross-linking almost to the starting point with 
phloroglucinol (10 % dimer). Experimental variation might have obscured an actual 
inhibition by thiocyanate when added with reagent HOBr. Ascorbate had no effect 
both when added with HOBr or in the enzymatic system. 
 
Figure 51. The effects of peroxidase substrates and HOX scavengers on the cross-
linking of collagen IV. Densitometry analysis of dimer formation in uncross-linked 
isolated ECM by 100 µM reagent HOBr (black bars) or enzymatic system using 100 µM Br⁻ 
and 100 µM H2O2 (grey bars), and comparing the effects of 100 µM iodide, thiocyanate, 
ascorbate and urate in both systems. N=2 ± range. ns, not significant, ** < 0.007, by multiple 








3.2.8 The effects of scavengers of HOBr on collagen IV cross-linking 
Methionine, reduced glutathione (GSH), thiodipropionic acid (TDPA) and NADH are 
all efficient scavengers of HOBr (structures shown in Figure 52). The rate constants 
of their reactions with HOBr are 4⨯106, 1⨯107 (estimated), 1.1⨯106, 4⨯106 M-1 s-1, 
respectively) (14, 102, 120). When present during the reaction of peroxidasin in the 
ECM with Br¯ and H2O2, all gave concentration-dependent inhibition of collagen IV 
dimerisation (Figure 53a, b). Thiodipropionic acid was the most effective, with 
almost complete inhibition at 5mM. Methionine, GSH and NADH had moderate 
effects on cross-linking.  
I also compared the effect of TDPA in the cell culture system and decellularised ECM. 
TDPA had a stronger inhibitory effect in the isolated decellularised ECM system 
(Figure 54). This could be due to it reacting with other components in the growth 









Figure 52. The chemical structures of NADH, GSH and TDPA. 
  





   
 
Figure 53: The effects of scavengers of HOBr on the cross-linking of collagen IV. (a) 
Commassie-stained gel showing dimer formation after treating uncross-linked ECM for 1 
hr at 37°C in PBS with Br¯ + H2O2 in addition to different scavengers as labelled. (b) 
Densitometry analysis of dimer formation when treated only with 100 µM Br¯ + 50 µM H2O2 
only (white bar), or in addition to NADH, GSH, methionine, or TDPA (0.2 mM in light grey 
bar, 1 mM in dark grey bars, 5 mM in black bars). ECM digestion, purification of NCD and 
analysis of dimer as in Figure 42. Values represent mean of ≥3 independent experiments ± 
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Figure 54: The effect of TDPA on the cross-linking. Comparing the effect of TDPA on 
dimer formation when added to cell culture medium during deposition of ECM () versus 
when added during the cross-linking reaction in the isolated uncross-linked ECM (). ECM 
digestion, purification of NCD and analysis of dimer as in Figure 42. Values represent mean 
of ≥3 independent experiments ± SEM. 
 
  




3.2.9 The effects of MPO inhibitors on collagen IV cross-linking 
Various compounds have been developed as inhibitors of myeloperoxidase in 
experimental systems or as potential therapeutic agents, and there are other drugs 
that show inhibitory activity against myeloperoxidase. The ability of some of these 
compounds to inhibit peroxidasin-catalysed cross-linking of collagen IV in isolated 
decellularised ECM was tested (Figure 55). 4-Aminobenzoic acid hydrazide gave 
60% inhibition of dimer formation with ~10 µM. This is in the range that inhibits 
myeloperoxidase activity of stimulated neutrophils (IC50 values of 2.2 and 15 µM; 
(202)). The 2-thioxanthine, TX1, was less potent at inhibiting peroxidasin (IC50 ~20 
µM) and is therefore much more specific for myeloperoxidase (IC50 ~1µM with the 
purified enzyme or neutrophils, (203)). Acetaminophen (paracetamol), at 
concentrations in the therapeutic range (up to 150 µM) that inhibit neutrophil 
myeloperoxidase (IC50 ~100 µM) (204) had little effect on the amount of dimer 
formed (IC50 >1mM).  
  










Figure 55: The effects of inhibitors of myeloperoxidase on the cross-linking. ECM 
from epithelial cells grown with PHG was treated with 100 µM Br¯, 50 µM H2O2 and the 
indicated concentrations of (a) ABAH, (b) TX1, and (c) acetaminophen, for 1 hour at 37°C 
in PBS. Chemical structures are shown next to each graph. ECM digestion, purification of 
NCD and analysis of dimer as in Figure 42. Values represent mean of ≥3 independent 
experiments ± SEM. Complete inhibition of the reaction would leave the 10% dimer already 
present in the untreated ECM.  





In this chapter I provided evidence that peroxidasin is present and active in the ECM 
as shown by mass spectrometry, western blotting, Amplex red assay and cross-
linking of collagen IV. The isolated decellularised ECM proved to be a useful model 
to study the enzymology of peroxidasin in situ. The formation of dimer in the non-
collagenous domain can be used to probe for the activity of peroxidasin both in the 
cell culture system and the isolated decellularised ECM system. I found that the 
cross-linking of collagen IV at the non-collagenous domain required the activity of 
peroxidasin, bromide and hydrogen peroxide, in agreement with the published 
findings (33).   
Collagen IV protomers (triple helices) are large and require special secretion 
vesicles to the extracellular matrix (205). It is not known definitively whether the 
site of forming the sulfilimine cross link in the NCD of collagen IV is intracellular or 
extracellular. In this chapter, I showed that peroxidasin embedded in the isolated 
decellularised ECM was able to cross-link the uncross-linked collagen IV in the 
presence of Br⁻ and H2O2. This indicates that cross-linking of collagen IV can occur 
extracellularly, which aligns with the findings that extracellular chloride 
concentrations are necessary for the oligomerization of collagen IV in an orientation 
that allows the NCD to be cross-linked (160). This finding does not rule out the 
possibility that any cross-linking also occurs intracellularly. Reagent HOBr and 
taurine bromamine were also able to generate the cross link, however less 
efficiently than the enzymatic system. The ability of a bromamine to promote the 
sulfilimine bond formation is consistent with published data that bromamines 
generate a sulfilimine link in peptides containing Met and Lys (172). It is possible 
that these secondary oxidants also play a role in cross-linking collagen IV.  
The extent of cross-linking in the isolated decellularised ECM showed bromide 
dependency and approached its maximum at bromide concentrations within the 
physiological plasma range (20-100 µM) (206). Cross-linking collagen IV was the 
first essential biological function of bromide in mammals to be discovered (35). The 




plasma concentration of bromide is maintained through diet and renal excretion. 
The effect of bromide deficiency in humans is yet to be studied.   
Peroxidasin embedded in the isolated decellularised ECM showed peroxidase 
activity as shown by its ability to oxidise Amplex red. It also oxidised exogenous 
NADH to its bromohydrin, and this shows definitively that peroxidasin in the 
isolated decellularised ECM produces HOBr. Previous evidence showed that 
peroxidasin (purified from transfected HEK293 cells) was able to halogenate 
taurine to haloamines (33). 
Cross link formation, Amplex red oxidation and NADH bromohydrin formation all 
followed a similar time course that reflected the rate of H2O2 consumption. This 
suggests they all depend on H2O2 / peroxidasin activity. Only a small fraction of the 
added H2O2 (~1 µM), however, was used by peroxidasin. The majority of the H2O2 
was consumed by what appeared to be a heme enzyme with catalase-like activity. 
This enzyme was a complicating factor in studying the kinetics of peroxidasin in 
situ.  
Calibration of the NADH assay against reagent HOBr indicated that peroxidasin in 
the ECM, plus 50 µM H2O2 generated approximately 250 nM HOBr in 15 minutes 
(Figure 39b, c). Over the same time, about 70 % of the H2O2 was consumed 
independently of peroxidasin (Figure 46a). Therefore, the HOBr trapped by NADH 
accounted for only 1% of the H2O2 consumed. As exogenous NADH inhibited cross-
linking by about 20 % (0.2 mM NADH in Figure 53c), it is estimated that low 
micromolar HOBr generated by peroxidasin would be sufficient to give maximum 
cross-linking (~70 %). However, 50 µM reagent HOBr did not give maximal cross-
linking, which implies that the enzymatic reaction is more selective for sulfilimine 
link formation. This might be due to peroxidasin being localised in the ECM or 
having an association with collagen IV which makes the reaction more targeted. It 
is noteworthy that efficiency of cross-linking by the enzymatic system is more 
remarkable when considering that catalase consumed most of the H2O2 added to 
the isolated ECM. 




The effects of NADH, GSH, methionine and TDPA on dimer formation also suggest 
selectivity of HOBr reactions toward cross-linking collagen IV over scavengers. 
They all exhibited inefficient inhibitory effect; high micromolar to millimolar 
concentrations were required, even though the scavengers are at least as reactive 
with HOBr as the Met and Lys residues that form the sulfilimine bond (120). This 
may indicate localised reactions of HOBr to cross link collagen IV that are not 
accessible for other scavengers. 
Iodide and thiocyanate are good substrates for peroxidases. In a study using a 
truncated recombinant form of peroxidasin, they were excellent two-electron 
donors. The rate constants of their reactions with compound I of the enzyme were 
1.68 and 1.83⨯107 M-1 s-1 respectively (13). These rate constants are in fact higher 
than that for bromide (5.6 ⨯ 106 M-1 s-1). However, none of these substrates 
promoted the cross-link. Rather, they acted as inhibitors in the presence of bromide, 
in line with previous evidence that iodide and thiocyanate inhibit the cross-linking 
reaction (33, 35). Iodide inhibited the cross link inefficiently (IC50 > 200 µM), at 
concentration much higher than the physiological concentration (< 1 µM). 
Thiocyanate, however, inhibited the cross link at concentrations that fall within the 
physiological range (20-120 µM). Thiocyanate also reacts with HOBr at almost 
diffusion-controlled rate (2.3 ⨯ 109), and its inhibitory effect can be due to 
scavenging some of the HOBr produced by peroxidasin. It is, however, surprising 
that thiocyanate does not lead to complete inhibition of the cross link, given that it 
is the best known substrate for peroxidasin and scavenger of HOBr. This again 
indicates high selectivity of the reaction of HOBr toward cross-linking collagen IV. 
This inhibitory effect might have implications, especially in smokers who have 
elevated levels of thiocyanate (207). Indeed, smoking was shown to be associated 
with changes in the basement membrane (208), which may be due to the inhibitory 
effect observed in collagen IV.  
Ascorbate had a minimal effect on the cross-linking of collagen IV in isolated ECM, 
even at 200 µM. This might have a physiological advantage, as plasma ascorbate 




levels in healthy individuals are normally in the range 50-70 µM. Urate had a modest 
inhibitory effect on dimer formation (IC50 ~20 µM), within the physiological range 
(200-400 µM, which can be higher in hyperuricemia) (209). Recently-submitted 
data from Obinger’s group show that ascorbate and urate reduce compound I of 
hsPxd01-con4 to compound II in two one-electron reduction steps (rate constants 
for the reactions with compound I are 7.2 and 1.9 ⨯ 104 M-1 s-1, respectively) (47). 
The rate of reduction of compound II to the native enzyme is slower, which leads to 
accumulation of compound II and loss of the halogenation activity. It is not clear 
why urate showed inhibitory effect on the cross-linking while ascorbate did not. It 
might be related to accessibility to the active site of the enzyme (their chemical 
structures are shown in Figure 50). 
The homology between peroxidasin and myeloperoxidase, and the interest in 
developing pharmacological inhibitors of myeloperoxidase motivated the 
investigation of how myeloperoxidase inhibitors affect peroxidasin and the 
sulfilimine cross-link. Acetaminophen is a moderate inhibitor of myeloperoxidases, 
while ABAH and TX1 are potent (203, 204, 210). In the isolated decellularised ECM 
system, only ABAH inhibited peroxidasin with comparable efficacy to inhibiting 
MPO. This would make it difficult to distinguish the two in a complex or in vivo 
system. However, TX1 was more specific for myeloperoxidase, and should not 
compromise its use for probing its pathophysiology.  
In summary, in this chapter I have optimized the isolated decellularised ECM as an 
experimental model suitable for the study of peroxidasin in situ. The formation of 
the sulfilimine cross link in isolated collagen IV required both H2O2 and bromide, 
and was inhibited by iodide, thiocyanate and urate. Peroxidasin embedded in the 
ECM was active and able to oxidise external substrates. HOBr was formed and 
released in the ECM, as evident by oxidation of NADH to bromohydrin. It is not 
known whether the HOBr produced by peroxidasin reacts selectively with collagen 
IV to form the sulfilimine bond or extends to other endogenous targets in the ECM.  
 
 




As shown in chapter 3, HOBr produced by peroxidasin in the ECM undergoes 
reactions that are not limited to the cross-linking of collagen IV. My focus in this 
chapter is to investigate the reactions of HOBr produced by peroxidasin with 
intracellular and extracellular protein targets.   
Hypobromous acid reacts with proteins, lipids, carbohydrates, DNA and 
antioxidants (Figure 13) (120). Cysteine, methionine, tryptophan and histidine are 
the most reactive amino acids with HOBr, followed by lysine and tyrosine. HOBr 
reacts with methionine to produce methionine sulfoxide and dehydromethionine 
(114). The reaction of HOBr with tyrosine leads to the formation of 3-
bromoytrosine and 3, 5-dibromotyrosine, which are stable and measurable 
biomarkers of HOBr-mediated damage (89, 132). HOBr reacts with amine groups to 
form bromamines, which retain some of the oxidising capabilities of HOBr and can 
undergo further reactions with other biological targets, including GSH, methionine 
and ascorbate (5).  
Hypohalous acid-mediated damage to ECM alters the structure and function of 
proteins, which can cause them to aggregate and fragment. It can change proteolytic 
susceptibility, modulate molecular recognition and compromise ECM integrity (12, 
211, 212). The ECM is particularly susceptible to oxidative damage due to limited 
extracellular antioxidant defence and its low turnover rate, which leads to 
accumulation of damage with age and disease (12). Oxidative damage to the ECM is 
implicated in many pathologies, including the development of atherosclerosis. 
Myeloperoxidase and eosinophil peroxidase have been implicated as the major 
culprits in exacerbating oxidative damage in inflammation (12, 129, 132, 185). The 




role of peroxidasin as a generator of HOBr in the ECM has only been recognised 
recently. The extent and the physiological consequences of peroxidasin-mediated 
oxidation of biomolecules are not yet known. Increasing evidence is implicating 
peroxidasin in many diseases, including cardiovascular diseases and some cancers 
(56, 68, 70). 
My aim in this chapter was to investigate whether peroxidasin leads to oxidative 
modifications of proteins. In particular, I studied oxidation of methionine and 
bromination of tyrosine residues on proteins. I also investigated the effects of other 
peroxidase substrates, namely thiocyanate, urate and nitrite in modulating these 
oxidative modifications in order to understand the specificity of the cross-linking 
reaction versus other reactions. Stable isotope dilution LC/MS/MS methods to 
measure methionine sulfoxide and 3-bromotyrosine were developed for 
application to ECM as detailed in Chapter 2.  
  




4.2. Detection of protein modifications 
4.2.1. Methionine sulfoxide in proteins 
The sulfilimine link in the non-collagenous domain forms between Met93 and Hyl211 
residues on two opposing protomers of collagen IV. Depending on the isomer of 
collagen IV, there is one or two other methionine residues adjacent to the site of the 
cross link (168). Here I investigated whether the activity of peroxidasin leads to the 
oxidation of other methionine residues in the cell culture system. 
Measuring methionine and its oxidised metabolites in proteins is inherently 
difficult due to its high susceptibility to oxidation during sample preparation. I 
encountered many technical challenges in developing a method to hydrolyse 
proteins and separate analytes by LC/MS/MS. After several months of optimisation, 
I was successful in measuring methionine sulfoxide with minimal artificial 
oxidation. To validate the method, ECM isolated from peroxidasin knock-out cells 
was treated with reagent HOBr then digested and analysed for methionine 
oxidation. The chromatogram in Figure 56a shows peaks of methionine and 
methionine sulfoxide. When the areas of the peaks were related to standard 
calibration curves of methionine and methionine sulfoxide, the percentage of 
oxidised methionine residues increased from 7% in the untreated ECM to 35 % after 
treatment with HOBr.  
I then measured methionine oxidation in intracellular extracts and ECM isolated 
from epithelial cells grown in the presence or absence of bromide or phloroglucinol, 
or ECM isolated from peroxidasin knock-out cells. Samples were digested with 
pronase then analysed by LC/MS/MS for methionine and methionine sulfoxide. 
Isotopically labelled internal standards were used for normalisation and 
monitoring artificial oxidation. Approximately 6 % of methionine residues on 
proteins in the intracellular extract were oxidised to methionine sulfoxide (Figure 
56b). Oxidation level was higher in the extracellular matrix, averaging at ~10 % of 
methionine residues on proteins. There was no significant difference between the 




levels of methionine sulfoxide with bromide or phloroglucinol treatment, or in 





Figure 56. Oxidation of methionine to methionine sulfoxide. (a) Chromatogram 
obtained in multiple reaction monitoring mode for methionine (m/z 150 to 104, black 
lines) and methionine sulfoxide (m/z 166 to 74, red lines) in decellularised ECM isolated 
from peroxidasin knock-out epithelial cells untreated (dashed lines) or treated with 100 
µM reagent HOBr (solid lines). (b) Levels of oxidised methionine residues on proteins in 
the intracellular extracts isolated by lysing cells in sodium deoxycholate as described in 
Section 2.2.2 (black bars), or in the isolated ECM (grey bars). Epithelial cells were grown 
either with culture medium only (untreated), or supplemented with 100 µM bromide or 
50 µM phloroglucinol. Peroxidasin knock-out cells were grown in culture medium alone. 
Cells were lysed and the intracellular lysates were separated from the ECM. All samples 
were digested with pronase then analysed by LC/MS/MS as described in Chapter 2. 
Values are means of 4-5 independent experiments ± SEM. *** p=0.0003, ** p=0.008, n.s. 
not significant by two-tailed paired t test. 
 




4.2.2. Peroxidasin leads to the formation of 3-bromotyrosine 
3-Bromotyrosine is one of the products of the reaction between tyrosine and HOBr. 
Here I investigated whether HOBr produced by peroxidasin reacts with tyrosine 
residues on proteins to form 3-bromotyrosine. Epithelial cells (WT or peroxidasin 
knock-out) were grown in culture for 6-8 days, with daily exchange of medium, in 
the presence or absence of the peroxidasin inhibitor phloroglucinol. Cells were 
lysed and ECM was isolated then hydrolysed to individual amino acids and analysed 
by LC/MS/MS (Figure 57). The same samples were also digested with collagenase 
and analysed by SDS-PAGE for dimer formation. The full method is described in 
Section 2.2.17.  
 
  
Figure 57. Procedure schematic. Epithelial cells (wild type or peroxidasin knock-out) 
were grown in the presence or absence of phloroglucinol. ECM was isolated and divided 
for processing and analysis by LC/MS/MS or SDS-PAGE. 
 
  




3-Bromotyrosine was detected in the ECM isolated from WT epithelial cells. The 
chromatogram in Figure 58 shows peaks for tyrosine and the two bromine isotopes 
of 3-bromotyrosine. Negligible amount of 3-bromotyrosine was detected in ECM 





Figure 58. Measuring 3- Br-Tyr in ECM. Chromatograms obtained in multiple reaction 
monitoring mode for tyrosine (m/z 182 to 136, solid line) and two bromine isotopes of 
3-bromotyrosine (BY1, m/z 260 to 214, red dashed line, and BY2, m/z 262 to 216, 
overlaid dotted black line) in ECM isolated from (a) wild type or (b) peroxidasin knock-
out epithelial cells. ECM was hydrolysed with methane sulfonic acid then analysed by 








The level of 3-bromotyrosine in ECM isolated from the WT cells was 1.13 mmol / 
mol tyrosine and decreased to 0.14 mmol / mol tyrosine when WT cells were grown 
in the presence of phloroglucinol. 3-Bromotyrosine level in ECM isolated from 
peroxidasin knock-out cells was 0.045 mmol / mol tyrosine (Figure 59a).  
Collagen IV cross link was analysed in the same samples. As described earlier, 
isolated ECM samples were digested with collagenase, and NCD was analysed by 
SDS-PAGE, Coomassie staining and densitometry quantification. Dimer formation 
mirrored the trend of 3-bromotyrosine formation (Figure 59b). Consistent with the 
results shown in Figure 42 in Chapter 3, when cells were grown in culture medium 
alone, dimer formation was approximately 75 % of the total NCD, which decreased 
to approximately 15 % when cells were grown in the presence of phloroglucinol or 
isolated from peroxidasin knock-out cells. 
I also tested for the formation of 3-bromotyrosine in the decellularised ECM 
incubated with bromide and hydrogen peroxide. Within one hour, 3-bromotyrosine 
level increased from 0.14 to 0.93 mmol / mol tyrosine (Figure 60a). There was no 
significant increase in the level of 3-bromotyrosine when only H2O2 or Br⁻ was 
added separately to ECM. A similar trend was observed in cross-linking collagen IV 
in the decellularised ECM (Figure 60b).  
  








Figure 59. Formation of 3- Br-Tyr and dimer in cell culture. (a) 3-Bromotyrosine 
levels in ECM isolated from PFHR9 cells cultured for 6-8 days in the absence (Untreated) 
or presence of phloroglucinol (PHG), or isolated from peroxidasin knock-out PFHR9 cells 
(PXDN-KO). (b) Densitometry analysis of dimer formation in the NCD isolated from the 
same conditions described in (a). All ECM samples were hydrolysed with methane 
sulfonic acid then analysed by LC/MS/MS as described in Chapter 2. Values are mean of 
3-8 independent experiments ± SEM. **** p <0.0001, *** p<0.001 by multiple comparison 
ANOVA analysis. The NCD was isolated and analysed as described in Figure 42. 
Densitometry values represent mean of ≥3 independent experiments ±SEM. 
 
  








 Figure 60. Formation of 3- Br-Tyr and dimer in decellularised ECM. (a) 3-
Bromotyrosine levels in ECM from cells grown in the presence of PHG, then isolated and 
treated with 100 µM Br⁻ and/or 50 µM H2O2 for 1 hour at 37°C. (b) Densitometry analysis 
of dimer formation in the NCD isolated from the same conditions described in (a). All 
ECM samples were hydrolysed with methane sulfonic acid then analysed by LC/MS/MS 
as described in Chapter 2. Values are mean of 3-8 independent experiments ± SEM. **** 
p <0.0001, ns, not significant by multiple comparison ANOVA analysis. The NCD was 
isolated and analysed as described in Figure 42. Densitometry values represent mean of 








4.2.3. The levels of 3-bromotyrosine increase with increasing bromide 
concentration 
To test the bromide requirement for the formation of 3-bromotyrosine during 
growth of cells, I cultured epithelial cells with daily supplementation of bromide. I 
then isolated the ECM and analysed it for 3-bromotyrosine as described earlier. It is 
worth noting that a trace amount of bromide is present in culture medium as 
contamination in sodium chloride, and was measured to be ~6 µM in 100 mM NaCl 
(35).  
The levels of 3-bromotyrosine increased slightly with increasing bromide 
concentrations, and appeared to saturate above 50 µM bromide (Figure 61a). 
Analysis of dimer formation in the same samples showed that cross-linking was 
near maximal with the trace amounts of bromide present in the culture medium 
(Figure 61b). 
The effect of bromide concentration was also tested in the decellularised ECM 
system. Uncross-linked ECM isolated from WT cells grown in the presence of 
phloroglucinol was decellularised and treated with hydrogen peroxide and 
increasing amounts of bromide for one hour. The levels of 3-bromotyrosine 
progressively increased from 0.1 to 1.4 mmol / mol tyrosine with 200 µM Br⁻ 
(Figure 62a). Dimer formation in the same isolated ECM increased with increasing 
bromide levels and reached maximum at 100 µM Br⁻ (Figure 62b).  
The results shown in Figure 59b and Figure 62a combined demonstrate that 
peroxidasin can catalyse the formation of 3-bromotyrosine extracellularly in the 
decellularised ECM. 
  








Figure 61. The effect of bromide supplementation on the formation of 3-Br-Tyr and 
dimer in cell culture. (a) 3-Bromotyrosine levels in ECM isolated from PFHR9 cells 
cultured for 6-8 days with daily supplementation of cell culture medium with the 
indicated concentrations of bromide. ECM samples were hydrolysed with methane 
sulfonic acid then analysed by LC/MS/MS as described in Chapter 2. Values are mean of 
4 independent experiments ± SEM (b) Densitometry analysis of dimer formation in the 
same conditions described in (a). The NCD was isolated and analysed as described in 
Figure 42. Densitometry values represent mean of ≥3 independent experiments ± SEM. 
 
  








Figure 62. The effect of bromide supplementation on the formation of 3- Br-Tyr 
and dimer in the isolated decellularised ECM. (a) 3-Bromotyrosine levels in ECM from 
cells grown in the presence of PHG for 6-8 days, then isolated and treated with 50 µM 
H2O2 and the indicated concentrations of Br⁻ for 1 hour at 37°C. ECM samples were 
hydrolysed with methane sulfonic acid then analysed by LC/MS/MS as described in 
Chapter 2. Values are mean of 3 independent experiments ± SEM (b) Densitometry 
analysis of dimer formation in the same conditions described in (a). The NCD was 
isolated and analysed as described in Figure 42. Densitometry values represent mean of 
3 independent experiments ± SEM. 
  




4.2.4. The levels of 3-bromotyrosine are higher in the ECM than in the 
intracellular extract 
It is unknown whether peroxidasin is active intracellularly or only upon secretion 
to the extracellular matrix. The formation of 3-bromotyrosine on proteins in the cell 
culture system can be used to track the activity of peroxidasin. To identify whether 
3-bromotyrosine is present intracellularly as well as extracellularly, I separated 
extracts from epithelial cells into intracellular lysate and ECM, then digested the 
ECM with collagenase to separate the NCD. The different fractions were hydrolysed 
and analysed by LC/MS/MS.  
The level of brominated tyrosine was very low in the intracellular fraction (0.13 
mmol bromotyrosine/ mol tyrosine) (Table 16). It increased slightly with bromide 
supplementation and decreased with phloroglucinol treatment. The level of 
brominated tyrosine was significantly higher in the ECM than in the intracellular 
lysate (Figure 63). Furthermore, the NCD contained significantly higher levels of 3-
bromotyrosine than the ECM. 
Table 16. The levels of 3-Br-Tyr in intracellular extract (ICE), extracellular matrix 
(ECM) and non-collagenous domain (NCD). Epithelial cells were grown in cell culture 
with medium alone (untreated), 100 µM bromide (+Br⁻), 50 µM phloroglucinol (PHG). 
Peroxidasin knock-out cells (KO) were grown in cell culture medium alone. Values are 
means of 4-5 independent experiments ± SEM. ns, not significant, *, p< 0.05, ** p<0.01 by 
multiple comparison one-way ANOVA of each treatment to the untreated respective 
fraction. 
 ICE ECM NCD 
Untreated 0.13 ± 0.04 1.06 ±0.14 1.49 ±0.25 
+ Br- 0.18 ±0.06 ns 1.43 ±0.22 ns 1.93 ±0.41 ns 
+ PHG 0.03 ±0.01 ns 0.13 ±0.04 ** 0.29 ±0.08 * 










Figure 63. Levels of 3- Br-Tyr in cellular lysate and ECM. Levels of 3-bromotyrosine in 
intracellular extract (ICE), extracellular matrix (ECM) and non-collagenous domain (NCD) 
when cells were grown in cell culture for 6-8 days in culture medium alone. All samples 
were hydrolysed with methane sulfonic acid then analysed by LC/MS/MS as described in 
Chapter 2. Values are mean of 4-5 independent experiments ± SEM. * p < 0.05, **** p 
<0.0001 by 2 way ANOVA analysis. 
 
  




4.3. Modulation of protein modifications 
4.3.1. Thiocyanate modulates the formation of 3-bromotyrosine  
As shown in Chapter 3, physiological levels of thiocyanate interfered with the cross-
linking of collagen IV (Section 3.2.7). Here I investigated whether thiocyanate 
modulated the formation of 3-bromotyrosine as well. For comparison, I also looked 
at cross-linking of collagen IV within the same samples. The cross-linking results 
presented here are independent biological replicates of experiments reported 
earlier in chapter 3.  
Here I used two experimental systems; a) adding thiocyanate to culture medium, 
and, b) adding thiocyanate to decellularised isolated ECM. In the cell culture system, 
increasing concentrations of thiocyanate (0 – 400 µM) were added to culture 
medium during cell growth, either alone or in combination with bromide (50 and 
100 µM) to test for substrate competition. 
The levels of 3-bromotyrosine in ECM isolated from epithelial cells decreased 
substantially with adding increasing concentrations of thiocyanate in the cell 
culture medium (Figure 64a). When no bromide was added, the maximum level of 
3-bromotyrosine was 1.2 mmol / mol tyrosine, which decreased progressively with 
thiocyanate concentration to 0.3 mmol / mol tyrosine (inhibition by 78%). When 
50 and 100 µM bromide were added to culture medium, the maximum levels of 3-
bromotyrosine were 1.9 and 2.1 mmol / mol tyrosine, respectively, which 
decreased with adding thiocyanate to 0.36 and 0.41 mmol / mol tyrosine (inhibition 
by 81% for both bromide concentrations). The IC50 increased with increasing 
bromide concentration (Table 17), which is indicative of competition between the 
two substrates.  
Analysis of dimer formation in ECM isolated from the same conditions described 
above showed that thiocyanate in cell culture led to progressive but quite modest 
inhibition of the cross-linking of collagen IV (Figure 64b). Adding bromide also 
provided protection from the inhibitory effect of thiocyanate. 








Figure 64. The effects of thiocyanate on the formation of 3- Br-Tyr and dimer in cell 
culture. (a) 3-Bromotyrosine levels in ECM isolated from PFHR9 cells cultured for 6-8 
days with daily treatment of increasing concentrations of SCN⁻ either without added Br⁻ 
(), or with added 50 µM () or 100 µM Br⁻ (). Cells were lysed and ECM was isolated, 
hydrolysed with methane sulfonic acid then analysed by LC/MS/MS as described in 
Chapter 2. Values are mean of 3 independent experiments ± SEM. Curves are nonlinear 
fit. (b) Densitometry analysis of dimer formation in the same conditions described in (a). 
Densitometry values represent mean of 3 independent experiments ± SEM. The grey 
dashed lines in (a) and (b) represent inhibition by 50 µM phloroglucinol (PHG). 
 
  




I also studied the effects of thiocyanate on 3-bromotyrosine and dimer formation in 
the decellularised isolated ECM system. Epithelial cells were grown in the presence 
of phloroglucinol for 6-8 days, the uncross-linked ECM was isolated and then 
treated with increasing concentrations of thiocyanate (0-400 µM), bromide (50 or 
100 µM) and 50 µM hydrogen peroxide for one hour.  
Similar to the results in the cell culture system, bromination of tyrosine residues in 
decellularised isolated ECM decreased with increasing concentration of thiocyanate 
(Figure 65a). Thiocyanate achieved near complete inhibition of 3-bromotyrosine 
formation in the isolated ECM. Increasing bromide concentration also led to an 
increase in IC50 (Table 17). Note that in the cell culture system peroxidasin can be 
active without adding bromide to the growth medium, as it contains residual 
amounts of bromide in sodium chloride. In contrast, adding bromide to the 
decellularised system was necessary for the activity of peroxidasin. Therefore I only 
compared two concentrations of bromide (50 and 100 µM).  
The maximal levels of 3-bromotyrosine and dimer formation were overall higher in 
the cell culture system than in the decellularised ECM system (Table 17, Figure 
64a and Figure 65a). Thiocyanate was more effective in inhibiting 3-
bromotyrosine formation than dimer formation both in the cell culture system and 
the decellularised system. 
  








Figure 65. The effect of thiocyanate on the formation of 3- Br-Tyr and dimer in 
decellularised ECM. (a) 3-Bromotyrosine levels in ECM isolated from PFHR9 cells 
cultured for 6-8 days with daily treatment of 50 µM PHG. Isolated ECM was treated with 
50 µM H2O2, Br⁻ 50 µM () or 100 µM (), and the indicated concentrations of SCN⁻ for 
1 hour at 37°C. ECM samples were hydrolysed with methane sulfonic acid then analysed 
by LC/MS/MS as described in Chapter 2. Values are mean of 3 independent experiments 
± SEM. Curves are nonlinear fit. (b) Densitometry analysis of dimer formation in the same 
conditions described in (a). Densitometry values represent mean of 3 independent 








Table 17. The formation of 3-Br-Tyr and its inhibition by thiocyanate. Maximum (Max 
BY) and minimum (Min BY) levels of 3-bromotyrosine when treated with 400 µM 
thiocyanate. Values are average of 3 experiments ± SEM. IC50 calculated by fitting 
exponential decay curves to data in Figure 64a and Figure 65a. *, p value < 0.05, ** < 0.01, 
*** < 0.001, comparing Min BY and Max BY of each column by two-tailed unpaired t test. 
  Br⁻ (µM) 
  Not added 50 100 
Cell culture 
system 
Max BY (mmol/ mol Y) 1.2±0.27 1.9±0.3 2.1±0.32 
Min BY (mmol/ mol Y) 0.27±0.03* 0.36±0.04** 0.4±0.04** 
IC50 (µM) 14 25 32 
Decellularised 
ECM system 
Max BY (mmol/ mol Y)  0.7±.03 1.0±0.03 
Min BY (mmol/ mol Y)  0.13±0.04*** 0.18±0.05*** 








4.3.2. Urate modulates the formation of 3-bromotyrosine  
As seen in Chapter 3, physiological levels of urate inhibited collagen IV cross-linking 
in the isolated decellularised ECM system. Here I investigated whether urate 
modulates the formation of 3-bromotyrosine in the cell culture system. The aim was 
to compare the ability of urate to compete as a substrate for peroxidasin and a 
scavenger of HOBr.  
Increasing concentrations of urate (0 – 400 µM) were added to the cell culture 
medium alone or in combination with 100 µM bromide. ECM was then isolated and 
analysed for 3-bromotyrosine and dimer formation. 
The levels of 3-bromotyrosine in the isolated ECM decreased slightly with 
increasing urate concentrations in culture medium (Figure 66a). When no bromide 
was added to the culture medium, the maximum level of 3-bromotyrosine was 1.2 
mmol / mol tyrosine, which decreased progressively to 0.7 mmol / mol tyrosine 
(inhibition by 42 %). When 100 µM bromide was added to culture medium, the 
maximum level of 3-bromotyrosine was 1.7 mmol / mol tyrosine, which decreased 
to 1.3 mmol / mol tyrosine at 400 µM urate (inhibition by 24 %). The effect of adding 
urate to culture medium on dimer formation was minimal (Figure 66b). 
Although fitting exponential decay curves to the data gives maximum inhibition and 
half inhibitory concentration (IC50), these values are approximation as inhibition 
observed here is modest with large experimental variation. Adding bromide 
provided protection against inhibition of 3-bromotyrosine formation and increased 
the IC50 from 77 to 195 µM urate (Table 18). Similar effect was observed on dimer 
formation (Figure 66b). 
  








Figure 66. The effect of urate on the formation of 3-Br-Tyr and dimer in cell culture. 
(a) 3-Bromotyrosine levels in ECM isolated from PFHR9 cells cultured for 6-8 days with 
daily treatment of the indicated concentrations of urate to cell culture medium, either 
without (), or with added 100 µM Br⁻ (). ECM samples were hydrolysed with methane 
sulfonic acid then analysed by LC/MS/MS as described in Chapter 2. Values are mean of 
5 independent experiments ± SEM (b) Densitometry analysis of dimer formation in the 
same conditions described in (a). The NCD was isolated and analysed as described in 
Figure 42. Densitometry values represent mean of 6 independent experiments ± SEM. 
The grey dashed lines in (a) and (b) represent inhibition by 50 µM phloroglucinol (PHG). 
 
Table 18. The formation of 3-Br-Tyr and its inhibition by urate.  Maximum (Max BY) 
and minimum (Min BY) levels of 3-bromotyrosine when treated with 400 µM urate. Values 
are average of 5 experiments ± SEM. IC50 calculated by fitting exponential decay curves to 
data in Figure 66a. ns, not significant difference between Min BY and Max BY by two-tailed 
unpaired t test. 
 Medium alone + 100 µM Br⁻ 
Max BY (mmol/ mol Y) 1.2±0.2 1.7±0.3 
Min BY (mmol/ mol Y) 0.68±0.2 ns 1.3±0.3 ns 
IC50 (µM) 77 195 
  




4.3.3. Nitrite modulates the formation of 3-bromotyrosine  
Nitrite is a peroxidase substrate and was shown recently to be a one-electron donor 
for hsPxd-con4, a truncated recombinant form of human peroxidasin (47). 
Therefore, I studied whether nitrite competes with bromide for peroxidasin in the 
ECM by looking at its effects on 3-bromotyrosine and dimer formation. Epithelial 
cells were cultured in media supplemented with sodium nitrite for 6 days. Cells 
were lysed and the ECM was isolated, washed thoroughly to remove any residual 
nitrite, hydrolysed and analysed by LC/MS/MS for 3-bromotyrosine and dimer 
formation.  
Nitrite inhibited the formation of 3-bromotyrosine. The levels of 3-bromotyrosine 
decreased progressively with increasing concentrations of nitrite (42 % inhibition 
at 200 µM nitrite) (Figure 67a). In contrast, the effect on dimer formation was 
minimal (13 % reduction at 200 µM nitrite) (Figure 67b). These results indicate 
that nitrite can modulate the reactions of peroxidasin and HOBr in the ECM.  
  








Figure 67. The effects of nitrite on the formation of 3- Br-Tyr and dimer in cell 
culture. (a) 3-Bromotyrosine levels in ECM isolated from PFHR9 cells cultured for 6 days 
with daily treatment of the indicated concentrations of sodium nitrite. ECM samples were 
hydrolysed with methane sulfonic acid then analysed by LC/MS/MS as described in 
Chapter 2. Values are mean of 3 independent experiments ± SEM. ** p= 0.0017 (Unpaired 
t test) (b) Densitometry analysis of dimer formation in the same conditions described in 
(a). The NCD was isolated and analysed as described in Figure 42. Densitometry values 
represent mean of 2 independent experiments. Range fell within symbol size. The grey 









4.4.1. Protein modifications 
The main aim of this chapter was to investigate whether the activity of peroxidasin 
causes oxidative modifications of proteins in the ECM. Oxidation of methionine 
residues in proteins in the cell culture system did not show a response to 
modulation of peroxidasin activity (stimulation with bromide or inhibition with 
phloroglucinol). Methionine sulfoxide can be reduced to methionine by the 
methionine sulfoxide reductase system (116). Any reversible increase in the levels 
of methionine sulfoxide might be transient and not measured in this assay. 
Therefore, the contribution of HOBr produced by peroxidasin to the oxidation of 
methionine residues on proteins could not be ruled out. The two methionine 
residues adjacent to the site of the sulfilimine cross link were reported to be 
oxidised (33). It was not clear whether it was the result of an enzymatic or 
artefactual oxidation. 
The analysis revealed that the levels of methionine sulfoxide were higher in the ECM 
than in the intracellular extracts. This might not be surprising, given that 
antioxidant defence systems are lower extracellularly than intracellularly (121), 
which might lead to accumulation of oxidised methionine residues in the ECM.  
The detection of 3-bromotyrosine is an exciting novel finding. To the best of my 
knowledge, this is the first evidence that peroxidasin activity leads to the formation 
of 3-bromotyrosine on proteins during cell growth in culture. Inhibition or knocking 
down of peroxidasin resulted in significantly lower levels of 3-bromotyrosine. 
The levels of 3-bromotyrosine increased with increasing bromide concentrations in 
cell culture and decellularised ECM. In comparison, maximal cross-linking of 
collagen IV was achieved with the trace amounts of bromide present in the culture 
medium and showed negligible increase with increasing bromide concentrations. 
This observation suggests that the reactions of HOBr produced by peroxidasin are 
specific for the cross-linking of collagen IV at low concentrations of bromide. Higher 




concentrations (still within physiological range) lead to increased production of 
HOBr, which might result in increased reactions with other targets. 
3-Bromotyrosine also formed in the isolated decellularised ECM when bromide and 
hydrogen peroxide were present, which confirms that peroxidasin is active and 
produces HOBr in the ECM. Higher concentrations of bromide were required in the 
isolated decellularised ECM to achieve equivalent levels of 3-bromotyrosine to that 
in cell culture. Similar results were observed in the effect of bromide concentrations 
on dimer formation. This might be due to different time scales of incubation; one 
hour in the isolated decellularised ECM versus 6-8 days in cell culture. Longer time 
of incubation might lead to accumulation of 3-bromotyrosine and dimer. Another 
possibility is that intact ECM may bind or concentrate bromide to a higher effective 
concentration than that of the medium. This compartmentalisation might be 
disrupted during the process of decellularisation and isolation of the ECM. 
Although low levels of 3-bromotyrosine were detected in the intracellular extract, 
the levels were significantly higher in the ECM. This is not surprising given that 
peroxidasin is secreted to the ECM where it is presumed to catalyse the cross-
linking of collagen IV. It is not certain whether the 3-bromotyrosine detected in the 
intracellular fraction is due to intracellular peroxidasin activity or contamination 
from solubilised ECM in the isolation process. The presence of peroxidasin was 
detected in the endoplasmic reticulum (22, 24). Cleavage of peroxidasin by 
proprotein convertase was shown to enhance its enzymatic activity, and is thought 
to occur extracellularly (27). This might be a regulatory mechanism to optimise 
cross-linking of collagen IV by peroxidasin extracellularly, while minimising 
oxidative damage intracellularly. Considering these observations, it is likely that 
intracellular 3-bromotyrosine is a residual contamination during the process of 
separation of intracellular lysate from the ECM. 
The levels of 3-bromotyrosine were significantly higher in the isolated NCD than in 
the ECM. The NCD accounts for approximately 14 % of collagen IV (~230 amino 
acids of the total ~1600-1700 amino acids in collagen IV, with slight variation in 




different isoforms). Collagen IV accounts for 50 % of the structural proteins in the 
basement membrane (Figure 17 in Chapter 1), meaning that the NCD is 
approximately 7% of the total structural ECM proteins. Therefore, it is highly likely 
that bromination of tyrosine in the ECM is not restricted to the NCD.  
The detection of 3-bromotyrosine provides evidence that HOBr produced by 
peroxidasin reacts with tyrosine residues on proteins. It suggests that the reactions 
of HOBr produced by peroxidasin are not limited to the sulfilimine link formation 
in collagen IV. It is noteworthy that the rate constants of the reactions of HOBr with 
some other amino acids are higher than with tyrosine (Figure 13 in Chapter 1). 
However, 3-bromotyrosine is used as a relatively stable biomarker for the 
production of HOBr and an indication that other modifications of amino acids are 
likely to occur. It is possible that HOBr also reacts with other biomolecules, such as 
lipids and carbohydrate moieties in the ECM (94, 95).  
3-Bromotyrosine is a biomarker of oxidative damage of tissues in various 
pathological conditions including asthma, sinonasal inflammation, cystic fibrosis, 
eosinophilic esophagitis and diabetes (132, 134, 213-216). It is elevated in 
bronchoalveolar lavage and urine obtained from asthmatic patients (139, 217) and 
used as a marker to assess their clinical responsiveness to pharmaceutical therapy 
(218). Brominated tyrosine can be metabolised by deamination and 
decarboxylation to form 4-hydroxyphenylacetic acid, and this urinary metabolite is 
also elevated in inflammation (219). Eosinophil peroxidase and myeloperoxidase 
secreted by activated phagocytes oxidise bromide and release potent brominating 
agents that cause tissue damage and oxidative modifications of proteins. While EPO 
and MPO are the main culprits known to date, the evidence I presented here 
demonstrates that peroxidasin also contributes to the formation of 3-
bromotyrosine. It also opens the door to investigating the role of peroxidasin in 
catalysing oxidative modifications in inflammation and other pathological 
conditions.  




4.4.2. Modulation of protein modifications 
Thiocyanate, urate and nitrite all inhibited the formation of 3-bromotyrosine to 
varying extents. The modulatory effect of thiocyanate on 3-bromotyrosine and 
dimer formation might be due to acting as a competitive substrate. This is 
supported by the kinetic data published recently which showed that thiocyanate 
reduces compound 1 of hsPxd-con4 faster than bromide (rate constants 1.83⨯107 
and 5.6⨯106 M-1 s-1, respectively) (13). Thiocyanate is also a scavenger of HOBr. The 
reaction of HOBr with thiocyanate is much faster than that with tyrosine (2.3⨯109 
and 2.6⨯105 M-1 s-1, respectively) (14, 101), which can account for the inhibition of 
3-bromotyrosine formation by thiocyanate. Relatively high concentrations of 
thiocyanate (400 µM) were required to achieve near maximal inhibition of 3-
bromotyrosine formation (inhibition by 50 µM phloroglucinol is set as maximal 
inhibition). It is puzzling that thiocyanate does not lead to a complete loss of 3-
bromotyrosine and dimer formation, given that it is the most efficient scavenger of 
HOBr reported to date. Based on the results presented in Chapter 3 and Chapter 4, 
it can be speculated that small amounts of targeted HOBr is sufficient for maximal 
collagen IV cross-linking. Inhibition of this targeted reaction remained moderate 
even at 400 µM thiocyanate. On the other hand, formation of 3-bromotyrosine 
requires higher concentrations of free HOBr, which can be scavenged by 
thiocyanate. These two models could explain the difference between the relatively 
efficient inhibition of 3-bromotyrosine formation by thiocyanate compared to its 
moderate inhibition of collagen IV cross-linking.   
Adding a higher concentration of bromide protected against inhibition of 3-
bromotyrosine and dimer formation, despite thiocyanate concentration being still 
higher than that of bromide (Table 17). These observations point to a competition 
between the two substrates. They also suggest a special affinity of peroxidasin for 
bromide and that selectivity is not determined solely by rate constants. The location 
and association of peroxidasin with the target protein might play a role in providing 
higher selectivity for bromide. 




Comparing the effects of thiocyanate in two experimental systems revealed that 
inhibition of tyrosine bromination by thiocyanate was more effective (lower IC50) 
in the cell culture system than in the decellularised isolated ECM (Table 17). This 
might be due to higher starting levels of 3-bromotyrosine in the cell culture system, 
which can be due to the difference in times of incubation, as explained earlier. It 
could also result from higher effective concentrations of bromide in the 
extracellular compartment in the cell culture system compared to the homogenous 
reaction mixture in the decellularised ECM system.  
Interestingly, adding bromide to the decellularised ECM system was necessary for 
peroxidasin to catalyse collagen IV cross-linking or 3-bromotyrosine formation, 
despite the reaction being carried out in phosphate buffer saline which contains 140 
mM sodium chloride. In contrast, adding bromide in the cell culture system was not 
necessary, as trace amount of bromide present as contamination in 110 mM sodium 
chloride in culture medium was sufficient for maximal cross-linking of collagen IV 
and formation of 3-bromotyrosine, as outlined in Sections 4.2.3 and 4.3.1. This again 
points to the possibility that the concentration of bromide might be higher in an 
intact ECM compartment in the cell culture system than in a homogenous reaction 
mixture in the decellularised ECM.  
Urate showed poor inhibition of 3-bromotyrosine, especially when the culture 
medium was supplemented with 100 μM bromide. Urate acts as a one-electron 
donor for peroxidases, and was shown recently to be a substrate for hsPxd-con4 
(47). The rate constant for the reduction of compound I of hsPxd-con4 by urate is 
lower than that for bromide (7.2 × 104 and 5.6⨯106 M-1 s-1, respectively). Urate 
slows the reduction of compound II to the native enzyme, leading to accumulation 
of the compound II, which does not enter the halogenation cycle. This could account 
for the modest inhibition observed here.  
Nitrite moderately inhibited the formation of 3-bromotyrosine by peroxidasin, and 
had a negligible effect on the cross-linking of collagen IV. Nitrite was recently shown 
to act as a one-electron donor for compound I of hsPxd-con4 (rate 1.9 × 105 M-1s-1) 




(47). Nitrite also reacts with HOBr (rate constant 1.4⨯104 M-1 s-1) (220, 221) and 
that might contribute to its moderate inhibition of 3-bromotyrosine formation 
observed here.  
Notably, thiocyanate, urate and nitrite all showed greater inhibitory effects on the 
generation of 3-bromotyrosine than on the formation of the sulfilimine link in 
collagen IV. This disparity indicates selectivity for the targeted reaction with 
collagen IV over the collateral reaction with tyrosine residues on proteins. It is also 
possible that the two reactions occur through different mechanisms; an enzyme-
bound intermediate and freely-diffused HOBr. Kinetic studies using the native full 
length peroxidasin should reveal peroxidasin substrate preference and 
competition, and explain this observation. Access to a pure active native 
peroxidasin is currently limited due to technical challenges in expressing and 
purifying it. Peroxidasin is a large multi-domain highly-glycosylated homotrimer 
that requires heme insertion, modification and covalent linkage (26).  
In summary, I presented here the first direct evidence that 3-bromotyrosine is a 
product of peroxidasin activity. With this finding, peroxidasin joins eosinophil 
peroxidase and myeloperoxidase as contributors to the formation of 3-
bromotyrosine, a biomarker for oxidative modifications in a number of pathological 
situations. This is in line with a hypothesised role of peroxidasin in protein 
halogenation in experimental diabetes (187). There is a plethora of evidence that 
hypohalous acid-derived damage to ECM proteins alters the function of proteins 
and promotes diseases. Further investigation is needed to understand the 
contribution of peroxidasin, as a resident ECM protein, to the formation of specific 
biomarkers of oxidative damage in pathological situations.   
 




Nitrite is a substrate for peroxidasin (47) and can modulate its bromination of 
tyrosine, as shown earlier in Chapter 4. With this observation, I asked the question 
whether peroxidasin activity leads to nitration of tyrosine residues on proteins. 
Peroxidases react with nitrite to produce nitrogen dioxide radicals (•NO2). 
Peroxidases also react with tyrosine residues to produce tyrosyl radicals, which 
react with nitrogen dioxide radical to form 3-nitrotyrosine (Figure 68). The 
physiological levels of nitrotyrosine are generally very low, due to competing 
alternative reactions for nitrogen dioxide and tyrosyl radicals (142, 222). 
Nonetheless, nitration of tyrosine residues can profoundly alter protein structure 
and function, such as decrease in the pKa of the hydroxyl group on the phenol ring. 
The bulky nitro group can also add steric hindrance, lead to conformation changes 
and interfere with tyrosine phosphorylation (127). It is also an indicator of other 
potentially deleterious reactions of nitrogen dioxide. Nitrotyrosine has been 
detected in a variety of tissues and fluids including urine and plasma (122). It is 
used as a biomarker for oxidation, and is elevated in atherosclerotic lesions (126, 
223). The baseline molar ratio of nitrotyrosine to tyrosine is estimated to be 1:106 
in proteins, although discrepancies in reported qualitative data on nitrotyrosine 
span several orders of magnitude (224). 
Qualitative and quantitative analysis of nitrotyrosine is technically challenging. One 
of the key issues is artefactual nitration, due to ubiquity of nitrating agents and 
reactivity of the phenol group on tyrosine (224). Acid hydrolysis of proteins at high 
temperature leads to increased artefactual formation of nitrotyrosine.  




My aim in this chapter was to develop a method to measure 3-nitrotyrosine and 
minimise these technical issues in order to investigate whether the activity of 
peroxidasin in the ECM leads to the generation of 3-nitrotyrosine on proteins.  
 
Figure 68. Mechanism for the formation of 3-NO2Tyr.  Peroxidases oxidise tyrosine to 
form tyrosyl radical and nitrite to form nitrogen dioxide. These two radicals react to form 
3-nitrotryosine.  
  





5.2.1 Liquid chromatography and mass spectrometry 
I optimised the LC/MS/MS method using standards of tyrosine and 3-nitrotyrosine, 
and isotopically labelled internal standards (13C6 Tyr and 13C9 3-NO2-Tyr) for 
normalisation and monitoring artefactual nitration (198). The chromatograms in 
Figure 69 show the peaks for unlabelled and labelled tyrosine eluting around 2.5 ± 
0.2 minutes, and unlabelled and labelled 3-nitrotyrosine eluting around 6.6 ± 0.2 
minutes. The sensitivity of detection of 3-nitrotyrosine in the mass spectrometer is 
higher than that for tyrosine. This is an advantage as it is to be expected that 3-
nitrotyrosine in the sample is only a small fraction of tyrosine. Therefore, the 
amounts used in the standard calibration curve are in in the nanomole range for 
tyrosine and picomole range for 3-nitrotyrosine. Artefactual nitration was 
monitored by measuring nitration of 13C6 tyrosine to 13C6 3-nitrotyrosine.  
  








Figure 69. Separation and detection of tyrosine and 3- NO2Tyr by LC/MS/MS. 
Chromatogram obtained in multiple reaction monitoring mode for (a) tyrosine (m/z 182 
to 136, eluting at 2.5 minutes) and 3-nitrotyrosine (m/z 227 to 181, eluting at 6.6 
minutes) and (b) isotopically-labeleled 13C6 tyrosine (m/z 188 to 171), 13C9 3-
nitrotyrosine (m/z 236 to 189) both eluting at the same times as their respective 
unlabelled counterparts in (a). The artefactual nitration was checked by monitoring 
conversion of 13C6 tyrosine to 13C6 3-nitrotyrosine (m/z 233 to 216, red line). 
 
  




5.2.2 Sample preparation for protein analysis 
After establishing the LC/MS/MS method, I tested the protein hydrolysis method on 
the isolated ECM. Briefly, ECM samples were hydrolysed with hydrochloric acid 
(HCl) supplemented with 1% phenol, and analytes were extracted by solid phase 
extraction (Figure 70). The full method is described in Chapter 2. 
Analysis of samples revealed abnormally high levels of artefactual nitration (Figure 
71a). This was only observed in samples but not in standards that were injected 
directly without prior processing, which indicated that artefactual nitration was 
occurring during sample preparation. Furthermore, I observed artefactual nitration 
when I mixed internal standards with HCl without heating. Testing different 
hypotheses to eliminate the source of nitration revealed that double deionized tap 
water contained a nitrating agent that reacted in HCl. I overcame this problem by 
using HPLC-grade bottled water, which minised artefactual nitration to the baseline 
observed in standards injected directly (Figure 71b).  
 






Figure 70. Schematic diagram of sample preparation for analysis by LC/MS/MS. 
Samples were mixed with internal standards, hydrolysed with HCl for 18 hours at 110°C 
then extracted by solid phase extraction using trifluoroacetic acid (TFA) and methanol 
(MeOH). The eluate was dried in the Speedvac then reconstituted in HPLC-grade H2O 
with 0.1 % formic acid (FA) and analysed by LC/MS/MS. 
  








Figure 71. Artefactual nitration during sample preparation. Chromatograms 
obtained in multiple reaction monitoring for 13C6 Tyr (black lines) and artefactual 
formation of 13C6 NO2-Tyr (red lines). In both chromatograms, 6 nmol of 13C6 Tyr were 
injected directly (solid lines), or mixed with HCl then extracted with solid phase 
extraction, using (a) double deionized tap water or (b) HPLC-grade bottled water in all 
preparation steps.  
 
  




After eliminating the main source of artefactual nitration, I proceeded to ECM 
sample processing using HPLC-grade H2O in all steps. The results revealed 
unusually high levels of 3-nitrotyrosine in ECM samples after hydrolysis and solid 
phase extraction. Puzzlingly, this was observed even in negative controls where I 
only added isotopically-labelled internal standards or only HCl immediately before 
solid phase extraction. To identify whether 3-nitrotyrosine is incidental to solid 
phase extraction, I tested different analytes separately (unlabelled and labelled 
tyrosine and 3-nitrotyrosine) before and after solid phase extraction. When each 
analyte was injected directly, 3-nitrotyrosine peak was detected only in the tube 
where it was added (Figure 72a). However, when the same analytes were 
processed by solid phase extraction first before injection, 3-nitrotyrosine peaks 
were detected in all other tubes, even the ones where no 3-nitrotyrosine was added, 
which indicated possible contamination with 3-nitrotyrosine during processing. To 
test this hypothesis, I analysed samplings of all the reagents used for acid hydrolysis 
and solid phase extraction. Indeed, the stock of TFA in standard use for washing 
steps during solid phase extraction was contaminated with 3-nitrotyrosine (Figure 
72b). I overcame the contamination problem by using a fresh stock of TFA. 
After troubleshooting and optimisation, I repeated the analysis of ECM samples. I 
encountered another issue with poor recovery of internal standards following 
hydrolysis and solid phase extraction, especially the isotopically labelled 3-
nitrotyrosine. The chromatogram in Figure 73 shows partial loss of both 13C6 Tyr 
and 13C9 NO2-Tyr after brief mixing with HCl and solid phase extraction. When the 
analytes were heated at 110°C in HCl then processed by solid phase extraction, 13C9 
3-NO2-Tyr was completely lost. This poor recovery of 13C9 3-NO2-Tyr after 
hydrolysis and solid phase extraction varied between samples (~ 0.1 - 10%), while 
recovery of 13C6 Tyr was ~20 % on average. This was an issue because it indicated 
likely loss of 3-nitrotyrosine (the analyte of interest) in the samples as well. It also 
hindered normalisation to internal standards and relative quantification. 
  








Figure 72. Testing for the source of contamination with nitrotyrosine. (a) The 
presence of 3-nitrotyrosine tested before and after solid phase extraction. Standards and 
internal standards; Tyrosine (Y, 13C6 Y) and 3-nitrotyrosine (NY, 13C9 NY) were either 
made in HPLC-grade H2O with 0.1% formic acid and each injected separately for 
LC/MS/MS analysis (black bars), or mixed with HCl, processed with solid phase 
extraction (which included washing with HPLC-grade H2O supplemented with 0.1% 
(v/v) TFA and elution with methanol), then lyophilised and reconstituted in HPLC-grade 
H2O with 0.1% FA and each injected separately into LC/MS/MS (grey bars). (b) 3-
Nitrotyrosine peak areas in samplings from different reagents used in sample 
preparation; methanol (MeOH), two different stocks of trifluoroacetic acid (TFA) and 
formic acid (FA). N.D. nothing detected. 
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Figure 73. Recovery of internal standards after sample preparation. (a) 
Chromatogram for 6 nmol of 13C6 Tyr (black lines) and 6 pmol of 13C9 NO2-Tyr (grey lines) 
when injected directly without processing (solid lines), or when mixed with HCl (without 
heating) and extracted with solid phase extraction (dashed lines), or when mixed with 
HCl and heated at 110°C for 18 hours then processed with solid phase extraction (red 
solid line). (b) Analyte peak areas for 13C6 Tyr (black bars) and 13C9 NO2-Tyr (grey bars) 








5.2.3 Detection of 3-nitrotyrosine in the ECM 
Despite the numerous technical issues I encountered in optimising this method, I 
was determined to attempt to answer the question whether 3-nitrotyrosine is 
present in the ECM. Here, ECM samples isolated from epithelial cells (wild type and 
peroxidasin knock-out) were hydrolysed to individual amino acids and prepared 
for analysis as described earlier. I used HPLC-grade water in all steps to minimise 
artefactual nitration, and a fresh stock of TFA that was tested negative for 
contamination with 3-nitrotyrosine. To estimate the amounts of 3-nitrotyrosine in 
ECM samples, despite loss of internal standards during processing, I used analyte 
peak areas for the standard calibration curve without normalisation to internal 
standards (Figure 74). The isotopically-labelled analytes were used for 
identification and confirmation of elution times. 
I was able to detect 3-nitrotyrosine in ECM isolated from wild type epithelial cells 
grown in culture medium supplemented with 200 µM nitrite (Figure 75a). The 3-
nitrotyrosine peak eluted at 6.4 minutes, consistent with the transitions and elution 
times for 3-nitrotyrosine (m/z 227 to 181) and 13C9 3-nitrotyrosine (m/z 236 to 
189) in standards (Figure 69). The peak area for 3-nitrotyrosine was 2.1⨯105, 
which is calculated to be 27 fmol on the standard calibration curve (Figure 74b). 
The peak area for tyrosine was 1.1⨯108, which is calculated to be 2 nmol on the 
standard calibration curve (Figure 74a). These values give a ratio of 13 µmol 3-
nitrotyrosine/ mol tyrosine. This ratio is an estimation, as it does not account for 
losses of tyrosine and 3-nitrotyrosine. The level of 3-nitrotyrosine in ECM isolated 
from peroxidasin knock-out cells was below the limit of quantification (peak area 
8.4⨯103) (Figure 75b).  
 
  








Figure 74. Standard calibration curve for tyrosine and 3-NO2Tyr. Peak areas for 
standard dilutions of (a) tyrosine and (b) 3-nitrotyrosine injected directly into the liquid 
chromatography column without SPE. Inset shows signal-to-noise ratio for 100 fmol 3-
nitrotyrosine. Values are average of three independent experiments ± SEM.  
 
  








Figure 75. 3-Nitrotyrosine in hydrolysed ECM. Chromatograms obtained in multiple 
reaction monitoring mode for tyrosine (m/z 182 to 136, black lines) and 3-nitrotyrosine 
(m/z 227 to 181, red lines) in ECM from (a) wild type or (b) peroxidasin knock-out 
epithelial cells grown in culture medium supplemented with 200 µM NaNO2. Samples 
were prepared by isolation and thorough washing of the ECM, hydrolysis with HCl, then 
processing by solid phase extraction and analysis by LC/MS/MS. 
 
  




5.2.4 3-Nitrotyrosine increases with increasing nitrite concentration 
Here I investigated the effect of adding increasing concentrations of nitrite on the 
formation of 3-nitrotyrosine during cell growth. The isolated ECM was washed 
extensively to remove any nitrite before acid hydrolysis and analysis by LC/MS/MS 
for the presence of 3-nitrotyrosine. The preliminary results in Figure 76a indicate 
that the formation of 3-nitrotyrosine on proteins in the ECM increased with 
increasing concentrations of nitrite. Values in the graph are analyte peak areas that 
were not normalised due to low recovery or loss of isotopically labelled internal 
standards. The results presented here are from one experiment only. Although 
multiple independent biological experiments were conducted, several repeats of 
measurements did not yield usable data due to the technical challenges outlined 
earlier. I calculated the relative amounts of tyrosine and 3-nitrotyrosine in the 
samples using the standard calibration curve in Figure 74 without normalisation 
to internal standards. Although absolute values are not reliable, the observed 
increase in 3-nitrotyrosine from 3 to 13 µmol / mol tyrosine is consistent with 
nitrite-dependent nitration in cell culture (Figure 76b). 
Secondly, I investigated the formation of 3-nitrotyrosine when decellularised 
isolated ECM was treated with nitrite and hydrogen peroxide for one hour. The 
preliminary results in Figure 77 (calculated using the standard calibration curve 
without normalisation to internal standards) show that 3-nitrotyrosine increased 
with increasing nitrite concentrations. When ECM isolated from peroxidasin knock-
out cells was incubated with nitrite and hydrogen peroxide, the ratios were 
approximately 2 µmol 3-nitrotyrosine / mol tyrosine, and did not increase with 
increasing nitrite concentration (Figure 77). 
While this is still work in progress, the pilot results presented here indicate that 
adding nitrite both during cell growth, or in decellularised ECM, led to formation of 
3-nitrotyrosine in ECM from wild type epithelial cells, while ECM from peroxidasin 
knock-out cells did not show this response.  








Figure 76. Formation of 3-NO2Tyr during cell growth. Epithelial cells cultured for 6 
days in media supplemented with the indicated concentrations of nitrite, then the ECM 
was isolated, hydrolysed and analysed for 3-nitrotyrosine by LC/MS/MS. (a) Peak areas 
of 3-nitrotyrosine (black bars) and tyrosine (grey bars). (b) Ratios of 3-nitrotyrosine to 
tyrosine when the peak areas were related to the standard calibration curve in Figure 
74 without normalisation to internal standards. 
 
  






Figure 77. 3-NO2Tyr increased with increasing nitrite concentrations in 
decellularised ECM. Ratios of 3-nitrotyrosine to tyrosine when the peak areas were 
related to the standard calibration curve in Figure 74 without normalisation to internal 
standards. ECM was isolated from epithelial cells, wild type () or peroxidasin knock-out 
(), treated with 50 µM H2O2 and the indicated concentrations of NaNO2 for 1 hour at 
37°C, then washed extensively, hydrolysed with hydrochloric acid and analysed by 
LC/MS/MS. Values for WT are from two independent experiments ± range. Values for KO 
are from one experiment.  
  
  





In this chapter I outlined the technical challenges I faced in optimising and 
validating a method for the analysis of 3-nitrotyrosine in proteins in the ECM, some 
of which I was able to overcome while others still require further work. In summary, 
I optimised the method for liquid chromatography and tandem mass spectrometry. 
I improved the sample preparation method to eliminate the main sources of 
artefactual nitration and contamination with 3-nitrotyrosine. It is worth noting that 
artefactual nitration of tyrosine is a common methodological issue, especially in the 
presence of acid (in hydrolysis or chromatography mobile phase) (225).  
Loss of the isotopically labelled 3-nitrotyrosine during sample processing continues 
to be an issue in this method. Mixing with HCl appeared to contribute to loss of the 
labelled 3-nitrotyrosine. It is also possible that using methanol to elute 3-
nitrotyrosine in the final step of the solid phase extraction might lead to methylation 
of 3-nitrotyrosine during lyophilisation in the speed vacuum concentrator and 
contribute to the loss of 3-nitrotyrosine. Using acetonitrile for the elution step might 
improve recovery. 
Pronase is an alternative way to digest ECM proteins to individual amino acids. 
However, I had limited success with this method. Further optimisation might 
improve digestion and minimise artefactual nitration. 3-Nitrotyrosine can also be 
detected by immunoblotting. There are two possible issues with using this method 
in this system: firstly, solubilising the ECM to be resolved by SDS-PAGE, and 
secondly, the low levels of 3-nitrotyrosine in this in vitro model might be below the 
level of detection by antibodies. However, it is worth trying this method to 
strengthen the evidence for 3-nitrotyrosine formation by peroxidasin.  
The technical issues and limitations for reliable analysis of protein tyrosine 
nitration are well documented in the literature (127, 224, 225). The abundance of 
nitrating agents in the environment (air, water) which can contribute to artefactual 
nitration, particularly on acidification, coupled with the prevalence of tyrosine over 




the extremely low levels of 3-nitrotyrosine in biological samples all make the task 
of accurate analysis of 3-nitrotyrosine levels exceedingly challenging. 
Nonetheless, I detected low levels of 3-nitrotyrosine in the hydrolysed ECM. 
Preliminary evidence presented here indicate that peroxidasin activity leads to 
formation of 3-nitrotyrosine. This is in line with the observation in Chapter 4 that 
nitrite modulates formation of 3-bromotyrosine by peroxidasin, and with recently-
submitted data that nitrite acts as a substrate for peroxidasin (47). Formation of 3-
nitrotyrosine increased with increasing concentrations of nitrite during cell growth 
and in decellularised isolated ECM. The preliminary results from peroxidasin 
knock-out ECM suggest that formation of 3-nitrotyrosine is peroxidasin dependent. 
Further work is planned and underway to confirm these findings. Although the 
levels measured here can only be approximated and cannot be accurately 
quantified, they are in the same order of magnitude that is reported in some 
literature. For example, exposure of human fibronectin to peroxynitrite led to the 
formation of 3-nitrotyrosine (40 µmol/mol tyrosine) (226).  
There are variety of pathways that lead to protein tyrosine nitration, including 
nitrating agents (e.g. peroxynitrite). Heme peroxidases (myeloperoxidase, 
eosinophil peroxidase and lactoperoxidase) are among the major sources of 
enzymatically derived nitration, especially in inflammation (119, 123, 227). The 
contribution of peroxidasin to protein nitration puts it among the enzymes that lead 
to oxidative damage, particularly in the ECM. Nitration can lead to altered protein 
structure and function, change in protein recognition, cell adhesion and 
proliferation (226, 228). 3-Nitrotyrosine is a biomarker for oxidative damage in 
inflammation. Antibodies against 3-nitrotyrosine were detected in patients with 
coronary artery disease, showing that oxidative modifications can be immunogenic 
(229). Nitration of tyrosine residues in α-synuclein is implicated in 
neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases (106). In 
this light, it is important to investigate the role of peroxidasin in protein tyrosine 
nitration in normal physiological processes and its contribution to abnormal 
pathological situations. 
 
Chapter 6  General Discussion  
 
6.1. Summary of findings 
The main aims of this research project were to investigate the activity and substrate 
specificity of peroxidasin in the ECM and to explore whether it mediates oxidative 
modifications of proteins other than cross-linking collagen IV. The graphical 
summary in Figure 78 highlights the main findings. 
In summary, I optimised a model system to study the activity of peroxidasin in situ, 
which demonstrated its requirement for hydrogen peroxide and bromide to 
catalyse the formation of the sulfilimine cross link in collagen IV. Physiological 
levels of bromide (<100 µM) were sufficient for maximal cross-linking. It is likely 
that very low levels of hydrogen peroxide are required (<1 µM), although its 
endogenous source remains elusive. Cross-linking collagen IV by peroxidasin in the 
decellularised ECM was more efficient than by adding reagent HOBr or taurine 
bromamine. The efficiency of peroxidasin in cross-linking collagen IV was especially 
apparent when considering the presence of a catalase that consumed most of the 
reagent hydrogen peroxide added to the decellularised ECM. Physiological levels of 
thiocyanate and urate modulated the formation of the sulfilimine cross link in 
collagen IV. One of the most exciting findings in this project was the detection of 
NADH bromohydrin, a fingerprint for the generation of HOBr by peroxidasin in the 
decellularised ECM.  
During the course of this research project, I optimised methods to measure 
oxidative modifications of proteins by LC/MS/MS. Methionine sulfoxide was higher 
in the ECM than inside the cells, but did not show association with the activity of 
peroxidasin. On the other hand, 3-bromotyrosine was a product of peroxidasin 
activity. It increased with increasing bromide concentrations and did not form 




when peroxidasin was inhibited by phloroglucinol or in peroxidasin knock-out cells. 
The levels of 3-bromotyrosine were higher in the non-collagenous domain than the 
ECM, which was higher than in the intracellular extract. Thiocyanate, urate and 
nitrite all modulated the formation of 3-bromotyrosine. Preliminary results showed 
that peroxidasin activity also led to the formation of 3-nitrotyrosine.  
 
Figure 78. Graphical summary of the main findings in this thesis. Peroxidasin oxidises 
bromide to hypobromous acid, which facilitates the formation of the sulfilimine cross link 
in the NCD of collagen IV in the ECM. HOBr undergoes other reactions with endogenous 
tyrosine residues on proteins producing 3-bromotyrosine and exogenous NADH producing 
bromohydrin. Peroxidasin reacts with tyrosine residues and nitrite producing their 
respective radicals. Nitrogen dioxide can react with tyrosyl radical to produce 3-
nitrotyrosine. Enclosed in the red frame are endogenous and exogenous substrates that 
modulate the activity of peroxidasin or the reactions of HOBr to varying extents. I⁻, iodide, 
SCN⁻, thiocyanate, NO2⁻, nitrite, PHG, phloroglucinol, NADH, nicotinamide adenine 
dinucleotide, TDPA, thiodipropropionic acid, ABAH, 4-aminobenzoic acid hydrazide.  
  




6.2. Significance and implications 
The discovery of the sulfilimine bond that results from the deliberate enzymatically-
catalysed oxidation of amino acids to cross link collagen IV (33) created a paradigm 
shift in the oxidative modifications by hypohalous acids. This case of constructive 
oxidative post-translational modification raises many curious questions about the 
enzymology of peroxidasin and its substrate specificity. Importantly, do 
peroxidasin activity and the production of HOBr lead to other, possibly damaging, 
oxidative modifications? Nelson et al. alluded to this conundrum in their seminal 
paper (15): 
“The concept of an extracellular peroxidase that is specifically attached to 
basement membranes opens up interesting new patho-physiological 
possibilities. Any metabolically hyperactive cell could secrete H202 and 
would be damaged, or be at least marked by a change such as lipid 
peroxidation, upon encountering an externally anchored peroxidase. A 
marked cell would then be subject to detection by scavenger receptors 
(Krieger et al., 1992), phagocytic attack and removal. This could be 
important during development, as indicated by studies in Drosophila, mouse 
embryos (Pierce et al., 1991) and, if a human homolog of peroxidasin exists, 
in an early response against epithelia-derived neoplasms.” 
The results presented in this thesis answer some of these questions, and raise some 
more.  
Firstly, peroxidasin reactions appear to be largely selective for, but not limited to, 
the cross-linking of collagen IV. The efficiency of the cross-linking reaction is higher 
when catalysed by the enzymatic system (bromide and hydrogen peroxide added 
to the decellularised ECM) than by the addition of reagent HOBr. This indicates 
selectivity of the reactions of HOBr with collagen IV conferred by peroxidasin, 
although the basis of this selectivity has not been demonstrated yet. It can be 
speculated that the selectivity arises from an association between peroxidasin and 
collagen IV or another protein in the ECM. It has been shown that the heme cavity 
of peroxidasin is not large enough to accommodate collagen IV for direct HOBr 
delivery (25, 26) and that peroxidasin does not form a stable complex with collagen 




IV (28). This does not rule out a transient interaction between peroxidasin and 
collagen IV or a ternary complex with a third ECM protein. This interaction might 
trigger a conformational change that may activate peroxidasin or enhance 
selectivity of its reactions (26). The presence of the non-catalytic LRR and Ig 
domains might enable such interaction. This hypothesis is supported by the 
observation that eosinophil peroxidase was inefficient in cross-linking collagen IV 
even in a cell overlay assay which induced spatial proximity with the ECM (28). 
Although EPO contains the catalytic peroxidase domain and is able to generate 
HOBr, it lacks the Ig and LRR domains. It seems plausible to propose that the 
additional non-catalytic domains in peroxidasin facilitate an orientation to target 
HOBr release in proximity to the non-collagen domain of collagen IV.  
Secondly, the enzymatic cross-linking of collagen IV proved resilient to competitive 
substrates of peroxidasin and scavengers of HOBr. Considering rate constants, 
thiocyanate is a better substrate for peroxidasin than bromide. The rate constant of 
the reaction of HOBr with thiocyanate is higher than that with methionine. 
Thiocyanate was more effective in inhibiting the formation of 3-bromotyrosine than 
the sulfilimine cross link. However, in both cases, inhibition was not as effective as 
predicted by rate constants of the reactions of thiocyanate with peroxidasin or with 
HOBr. Moreover, adding exogenous methionine (5 mM) to the decellularised ECM 
interfered only mildly with the cross-linking reaction. The mechanism of the 
formation of the sulfilimine cross link is hypothesised to involve bromination of 
methionine residue on collagen IV by HOBr. Given that methionine reacts with HOBr 
very rapidly, it is therefore perplexing that adding excess exogenous methionine 
does not scavenge all HOBr and completely stop the cross-linking reaction. All these 
observations suggest that there is more to the specificity of peroxidasin reactions 
than just the rate constants. They also clearly indicate a special affinity of 
peroxidasin for bromide, although the basis of this affinity is yet to be fully 
understood.  
It is important to keep in mind that the studies which reported the rates of reactions 
of peroxidasin with various substrates used a recombinant monomeric form of 
peroxidasin that contains only the peroxidase and Ig domains, which are necessary 




for its catalytic activity (13, 28, 47). This monomeric construct is active and 
provided extremely useful kinetic data on peroxidasin. However, as highlighted 
earlier, trimerisation and the presence of the other non-catalytic domains in 
peroxidasin might play a role in enhancing its affinity to bromide, or in altering the 
properties of the microenvironment to favour the cross-linking reaction with 
collagen IV.  
Modulation of peroxidasin activity by physiological levels of thiocyanate could be 
advantageous. Hypothiocyanous acid (HOSCN) can be generated either through 
two-electron oxidation of thiocyanate by peroxidasin or by reaction with HOBr. 
HOSCN is less reactive than HOBr (1, 230), and its formation could be a way to 
protect from the harmful effects of HOBr. It might not be a coincidence that 
thiocyanate has a greater inhibitory effect on the formation of 3-bromotyrosine 
(presumably a collateral reaction) than the formation of the sulfilimine cross link. 
Likewise, urate can act as an antioxidant and mitigate HOBr-mediated damage 
without interfering with its physiological role in cross-linking collagen IV.  
Thirdly, the detection of NADH bromohydrin shows that HOBr generated by 
peroxidasin in the decellularised ECM reacts with exogenous substrates. This 
indicates that HOBr produced by peroxidasin is released into the surroundings and 
its reactions are not limited to cross-linking collagen IV. Similarly, the detection of 
3-bromotyrosine demonstrates that HOBr reacts with amino acid residues on 
proteins in the ECM. It is worth highlighting that 3-bromotyrosine is not the main 
product of the reactions of HOBr with amino acids, as it reacts faster with cysteine, 
methionine, tryptophan, histidine, lysine and terminal amines (120). However, due 
to its relative stability, 3-bromotyrosine is used as a biomarker to identify the 
presence of oxidative modifications of proteins by HOBr. It is difficult to estimate 
the amount of HOBr generated by peroxidasin in the ECM, because it is highly 
reactive and generates different reactive intermediates and products. However, the 
results indicate that small concentrations of HOBr (low micromolar) are sufficient 
for the cross-linking reaction. The reactions of HOBr appear to be specific for the 
cross-linking of collagen IV at low amounts of bromide and hydrogen peroxide. 
Excess HOBr can undergo reactions with other targets.  




Finally, the novel finding that peroxidasin contributes to the formation of 3-
bromotyrosine and 3-nitrotyrosine has many implications. It brings peroxidasin to 
the spotlight as a resident contributor to oxidative damage of proteins in the ECM, 
a ubiquitous tissue with poor antioxidant defence. It also confirms the inkling that 
Nelson and colleagues have mentioned and raises many new questions about the 
patho-physiological roles of peroxidasin. These oxidative modifications might be 
one of the mechanisms by which peroxidasin plays a role in pathological situations 
such as hypertension, diabetes and ischemia-reperfusion injury (56, 63, 64, 67, 
187). In fact, evidence from a diabetic mouse model shows that halogenation of 
proteins in renal ECM impairs some protein functions and might be involved in 
diabetic glomerular injury (187). Peroxidasin might account for some of the 
oxidative damage to the ECM that is attributed to other heme peroxidases, such as 
myeloperoxidase and eosinophil peroxidase. Modifications of ECM proteins might 
be also one of the ways peroxidasin plays a role in cancer, especially when it is 
upregulated (17, 70, 73-75). Peroxidasin contributes to melanoma invasion, and 
silencing its gene blocks cellular invasion and adhesion (70). The mechanism is 
likely to involve epithelial mesenchymal transition (76, 78, 231). Being an 
extracellular protein, peroxidasin could also be a pharmaceutical target to impede 
tumour invasion.  
6.3. Limitations and future work 
Studying the activity of peroxidasin in situ as an alternative to the pure enzyme has 
advantages and disadvantages. It allows studying the enzyme in its native form and 
environment in the ECM and gives insight into the substrate specificity and 
modulation of the activity of peroxidasin. On the other hand, the ECM is a complex 
system that does not allow for pure kinetic studies of peroxidasin. For example, 
investigating peroxidasin requirement for hydrogen peroxide was complicated by 
the presence of a catalase in the ECM that appeared to consume most of the added 
hydrogen peroxide independently of peroxidasin. Studying substrate competition 
and inhibition was also complicated in this system, making it difficult to calculate 
kinetic parameters such as rate constants and the half maximal inhibitory 




concentrations. Furthermore, this model system is labour intensive and low 
throughput. Despite its limitations, studying peroxidasin in situ is a useful and 
versatile model system. It also highlighted some differences from the enzymology 
of the truncated variant hsPxd01-con4. 
One of the major challenges I encountered during this research project was setting 
up assays to quantify oxidative modifications in ECM proteins, particularly 
methionine sulfoxide and 3-nitrotyrosine. Many of the issues arise from the 
inherent chemical properties of these analytes and the artefactual oxidation and 
nitration. Work is underway to further optimise these assays.  
Research on peroxidasin is ironically hindered by its own intrinsic characteristics. 
The biosynthesis of this large multi-domain trimeric enzyme requires heme 
insertion, modification and covalent attachment, in addition to glycosylation in the 
endoplasmic reticulum and Golgi before secretion and cleavage by proprotein 
convertase. Recombinant expression and purification of a native and active 
peroxidasin is an exceedingly challenging quest, as reported in the literature and in 
personal communications with researchers at international conferences. 
Furthermore, probing for peroxidasin with immunoblotting was a frustrating 
endeavour. I tested multiple commercially available and custom-made anti-
peroxidasin antibodies, which showed low sensitivity, cross-reactivity or poor 
reproducibility. Research on peroxidasin would benefit from developing reliably 
specific and sensitive anti-peroxidasin antibodies that could be used in western 
blotting and immunohistochemistry. Access to a pure native and active peroxidasin 
would allow kinetic studies on its substrate preference, competition and inhibition. 
Solving the crystal structure of peroxidasin would help understanding the 
dynamism and mechanism of its activity. 
Notwithstanding these challenges, the findings in this thesis provide insights into 
the activity of peroxidasin in the ECM, as outlined earlier, and stimulation for 
further investigation. Some of the specific questions that remain to be answered 
relate to the basis of the affinity of peroxidasin for bromide over other substrates, 




such as thiocyanate. Elucidating the substrate preference and competition is 
essential for understanding the enzymology of peroxidasin. The source of hydrogen 
peroxide remains a mystery (49) and it would be interesting to pinpoint, as it is 
important for regulating the activity of peroxidasin. 
Little is known about the mechanism by which phloroglucinol inhibits the activity 
of peroxidasin and the cross-linking of collagen IV. Phloroglucinol is an inhibitor of 
peroxidases (232) and has been used in many studies to inhibit the formation of the 
sulfilimine bond in collagen IV (15, 33). It has been shown to have a cytoprotective 
effect against oxidative stress (233) and myocardial ischaemia–reperfusion injury 
in in vitro studies (64, 234). Phlroglucinol is used pharmacologically as an 
antispasmodic drug for treatment of variety of diseases, including irritable bowel 
syndrome and urinary tract infection (235, 236). It would be interesting to perform 
kinetic studies on the reaction of phloroglucinol with peroxidasin and other heme 
peroxidases. 
Future research can explore the interactive mechanism of peroxidasin and whether 
it binds to collagen IV or other ECM proteins to target HOBr release and limit 
nonspecific reactions. It will be interesting to investigate whether peroxidasin is 
active inside the cell or only upon secretion. Cleavage of peroxidasin by proprotein 
convertase was shown to occur primarily in the extracellular space (27). It also 
enhances the activity of peroxidasin, although the unprocessed enzyme is 
catalytically active. Current research conducted by my colleague Dr. Martina 
Paumann-Page shows that peroxidasin is constitutively secreted by melanoma cells 
to culture medium. It would be interesting to investigate the pattern of expression 
and functions in different developmental stages. Does peroxidasin serve functions 
other than cross-linking collagen IV, given that the ECM has a slow turnover rate? 
In this regard, future work can investigate the secretion of peroxidasin and its 
circulation in blood; how much and whether it is active. Work in our group is 
currently underway to optimise methods to address these questions. 




The jury is still out on the reaction mechanism of sulfilimine bond formation 
between two juxtaposed methionine and hydroxylysine residues on opposing 
protomers of collagen IV. It is proposed that HOBr reacts with methionine to form 
a halosulfonium cation intermediate which is then attacked by the amine group of 
hydroxylysine to produce the sulfilimine bond (35). Alternatively, HOBr can react 
with hydroxylysine to form a bromamine intermediate which is then attacked by 
the sulfide of methionine. The rate constants of the reactions of HOBr with 
methionine and lysine are 4⨯106 and 4⨯105 M-1 s-1, respectively (120), which 
suggests that the first reaction is more kinetically favourable. On the other hand, 
bromamine led to the formation of intermolecular sulfilimine bond in peptides 
containing methionine and lysine, suggesting that bromamine can be the 
intermediate in forming the intermolecular cross link in collagen IV (172). Further 
research should elucidate the reaction mechanism. 
Inhibition of collagen IV cross-linking by thiocyanate and iodide is interesting and 
warrants further investigation. Given that both thiocyanate and iodide are 
substrates for peroxidasin, it can be assumed that hypothiocyanous and hypoiodous 
acids are formed. However, the observed inhibitory effects of thiocyanate and 
iodide indicate that neither of their respective hypohalous acids promotes the 
sulfilimine cross link. This is interesting given that hypoiodous acid reacts with 
methionine to form dehydromethionine (114), which contains a sulfur-nitrogen 
bond analogous to that in the sulfilimine bond. Hypothiocyanous acid is unreactive 
with methionine (237). It may react with lysine to form an amino thiocyanate 
species that is not stable at physiological pH (238, 239). It would be interesting to 
test whether adding reagent hypoiodous acid and hypothiocyanous acid to 
monomeric collagen IV would generate the sulfilimine cross link. Future work 
should investigate the inhibition by these two substrates to shed more light on the 
chemical mechanism of the sulfilimine bond formation and the nature of the 
intermediates in this reaction. 
Another area of fertile investigation is the physiological functions of peroxidasin, 
which are likely to extend beyond cross-linking collagen IV. Multiple lines of 
evidence point to its role in redox regulation (39, 77) and antimicrobial defence (37, 




38). Peroxidasin is also proposed to play a role in wound healing by cross-linking 
tyrosine residues in the ECM (40).  
There is exciting potential in taking in vitro findings to in vivo models. In this regard, 
it would be interesting to study how the activity of peroxidasin is affected by 
bromide deficiency in humans, which may occur in certain diseases or as a result of 
kidney dialysis (240, 241). High levels of thiocyanate in smokers (242, 243) can lead 
to functional bromide deficiency, which results in thiocyanate outcompeting 
bromide. There is evidence that links smoking to alteration in the structure of 
basement membranes (208). Whether this is related to peroxidasin and the cross-
linking of collagen IV is yet to be explored.  
Future research should focus on the role of peroxidasin in post-translational 
modifications of ECM proteins. It would be interesting to investigate the effect of 
peroxidasin-catalysed tyrosine bromination on the structure and function of the 
modified proteins. Mapping the specific sites of protein tyrosine bromination and 
nitration would also provide further insight into the specificity of these reactions 
and peroxidasin interaction with other proteins. Peroxidasin can also form 
dityrosine (15), and it would be interesting to investigate its formation in the ECM. 
Protein tyrosine cross-linking leads to protein aggregation which are hallmarks of 
neurodegenerative diseases such as Parkinson’s and Alzheimer’s diseases (244, 
245). The role of peroxidasin in oxidative modifications is particularly interesting 
in pathological situations, such as diabetes and fibrosis, and in cancers where 
peroxidasin is upregulated. 
Despite taking strides forward in the last few years, research on peroxidasin is still 
relatively in its infancy. Future work on the activity and regulation of peroxidasin 
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